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ABSTRACT 
Background: Prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide, 
linked to the obesity epidemic. There is substantial research evidence for T2D 
prevention by lifestyle interventions in high-risk individuals. The span of this research 
provides a unique case study with which to critically examine general guidance for 
development and evaluation of interventions to improve health.  
My research question is how might can effective, equitable and sustainable service 
provision for T2D prevention in high-risk individuals be achieved? 
Methods:  Five papers reporting my empirical T2D prevention research form the core 
of my thesis. This research extends from the European Diabetes Prevention Study 
(EDIPS) RCT to the ‘New life, New you’ (NLNY) feasibility study. NLNY is a community 
based lifestyle intervention to reduce T2D incidence that is delivered by fitness trainers 
in North East England.  
To inform my research question I have reviewed intervention guidance history. I have 
then used T2D prevention as a case study, supported by my empirical research 
experience, to analyse this guidance  
Findings: Development of the NLNY intervention built on the EDIPS RCT evidence and 
experience. Pilot evaluation of NLNY suggests a feasible and acceptable intervention 
that is likely to be effective in preventing T2D.   Prevention of T2D provided a useful 
exemplar for analysis of intervention guidance and highlighted strengths and 
limitations of existing guidance models. This analysis led to a proposed new guidance 
framework. 
Conclusions: The NLNY intervention provides a potential service provision model for 
T2D prevention in high-risk individuals. Well planned effectiveness and cost-
effectiveness evaluation of the NLNY intervention is now needed. The analysis of 
intervention guidance and the proposed new framework will contribute to developing 
a robust study design. If effectiveness of the NLNY intervention is demonstrated there 
is potential for this community based intervention model to be further developed and 
adapted.  
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PREFACE 
I studied physiology and biochemistry for my first degree. During the course of study I 
became fascinated by the complexity of endocrinology, although at that time I thought 
insulin hormone was the ‘easy’ hormone. Also I was interested in the inter-relation of 
biochemical pathways, particularly links between glucose and fat metabolism in 
healthy physiology. However, after graduation I decided that laboratory science was 
not the right course for me at that time and I spent some years as a secondary school 
science teacher. My first post was as a physics teacher and I subsequently decided to 
keep with this subject area because I enjoyed the challenge involved in communicating 
complex concepts to young people in ways that facilitated their understanding. Thus, it 
was not until sometime later, when I joined Newcastle University as a public health 
researcher, that I revisited my original interest in healthy physiology and the biological 
determinants of disease. 
The public health and health promotion perspective on disease aetiology and 
preventive interventions is clearly different from the laboratory science and theoretical 
endocrinology approach to essentially the same subject area. However, a basic 
knowledge of the fundamental sciences that underpin the rationale for prevention of 
type 2 diabetes by lifestyle intervention adds a depth to my interest that contributes to 
a continuing fascination with the topic.  
I know that career pathways into public health are various and I believe that this 
variety of experience enriches discussions. I am pleased to have spent time as a 
practitioner, even though in the field of education rather than health, and I retain an 
empathy with real world practitioner perspectives. However, I have finally found the 
job I love to do and I am so grateful for the opportunity to study for my Doctorate. 
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CHAPTER ONE: INTRODUCTION 
 
Prevention of type 2 diabetes (T2D) falls within the sphere of health promotion, which 
is defined by the Ottawa Charter as ‘The process of enabling people to exert control 
over the determinants of health and thereby improve their health.’1 The large and 
rapidly increasing prevalence of T2D worldwide, the debilitating disease complications 
that affect people’s quality of life and incur high treatment costs, together with the 
potential for preventive intervention, make this a hugely important area of applied 
research. 2 Although there is a genetic predisposition associated with T2D,3, 4 it is 
essentially a lifestyle disease that is strongly linked to obesity and inactivity.5 Type 2 
diabetes (for description see chapter 3) can be prevented or delayed by lifestyle 
interventions.6  
My research question is how effective, equitable, and sustainable service provision for 
T2D prevention might be achieved. 
The concept of an evidence base as a desirable contribution, alongside other 
considerations, to health care practice is now well established.7 The use of evidence to 
support public health intervention provision for health improvement and disease 
prevention has a different focus and is less well defined. The challenges associated 
with disease prevention include the complexity of lifestyle interventions.8 Within 
public health, prevention of T2D is unusual as there is a substantial evidence base for 
T2D prevention. Evaluations of T2D preventive interventions for high-risk individuals 
include early feasibility studies, large randomised controlled trials (RCTs), ‘real world’ 
translational studies, and service provision models in some countries.9 10 The span of 
this research makes T2D prevention a uniquely suitable case study with which to 
analyse the utility of general guidance for the development and evaluation of complex 
interventions to improve health. 
My empirical T2D prevention research is reported in my five submitted papers that are 
listed above, introduced with contextual detail in Chapter six, and included in 
Appendices A to E.  These T2D prevention studies have been undertaken over several 
years. The Newcastle arm of the European Diabetes Prevention Study (EDIPS-
2 
 
Newcastle) was a clinical trial of lifestyle intervention for T2D prevention.11 The study 
protocol was based on the Finnish Diabetes Prevention Study (DPS).12 The DPS, 
together with EDIPS-Newcastle and the similar SLIM study from The Netherlands, 
formed the European Diabetes Prevention Study (EDIPS) collaboration. Following the 
completion of EDIPS-Newcastle we collated the EDIPS data. The first analysis of the 
EDIPS data forms the basis of my second submitted paper.13 The reduction in T2D 
incidence was similar in each of the contributory studies with a combined reduction of 
57% in the intervention groups compared with the control groups. Analysis of the 
weight loss intermediate health outcome data from EDIPS showed that those who 
achieved the target weight loss of at least 5% at one year had 65% lower T2D 
incidence. Maintaining weight loss for two or three years further reduced T2D 
incidence. The weight loss analysis of the EDIPS data was designed to support the 
evaluation of the ‘New life, New you’ (NLNY) pragmatic T2D preventive intervention 
feasibility study.14  
My remaining submitted papers report on the feasibility and acceptability of the NLNY 
intervention that was delivered by health and fitness trainers in leisure and community 
settings in Middlesbrough, UK.15, 16 The NLNY intervention lifestyle targets were 
modelled on the EDIPS study although the risk assessment, inclusion criteria, mode of 
delivery and study design were all different. The weight loss achieved at one year in 
the NLNY feasibility study was comparable to that achieved at one year in the EDIPS 
RCT. This encouraging primary outcome along with successful recruitment to the 
programme has led to the commissioning of the NLNY intervention as a service 
provision in Middlesbrough. However, the NLNY intervention effectiveness cannot be 
demonstrated without an experimental trial. 
In association with the NLNY feasibility study I conducted a qualitative study of 
participants’ perspectives of their behaviour change to support the further 
development of T2D preventive interventions.17, 18 The NLNY qualitative study is 
submitted in Appendix E as part of my thesis.  
The accumulated evidence and experience from the EDIPS and NLNY intervention 
studies and their associated qualitative studies underpin future research outlined in 
chapter eight. This includes a proposed cluster randomised controlled trial of the NLNY 
intervention. 
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In 2000 the Medical Research Council (MRC) proposed guidance for development and 
evaluation of complex interventions to improve health 19 This guidance was updated in 
2008.20 The MRC 2008 guidance framework was developed by a writing group with 
expert contributions. This framework has become influential both within and beyond 
the UK, is widely cited and might be considered a standard text. The MRC 2008 
framework sits within a historical timeline of similar guidance relating to the 
development and evaluation of complex interventions to improve health. 
To inform my research question I aim to: 
1. Review guidance for the development and evaluation of complex interventions 
to improve health and elicit important aspects of guidance frameworks. 
2. Introduce T2D, its aetiology and opportunities for preventive intervention. 
3. Review the literature to identify and select T2D prevention studies that 
illustrate different stages across the intervention development and evaluation 
spectrum from early feasibility studies to service provision. 
4. Analyse the selected T2D prevention studies with reference to the important 
intervention development and evaluation activities identified from my review 
of guidance frameworks. 
5. Present and reflect on my own T2D prevention work at Newcastle that has 
progressed in parallel with similar work elsewhere and that has underpinned 
and informed this guidance analysis. 
6. Use information from the preceding four aims (above) to outline the need for 
revised intervention guidance and propose a new framework diagram.  
In the final chapter I will discuss my empirical T2D prevention work and guidance 
analysis with the implications for policy, practice and future research.   
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CHAPTER TWO: REVIEW OF GUIDANCE FOR DEVELOPMENT AND EVALUATION OF 
COMPLEX INTERVENTIONS TO IMPROVE HEALTH 
 
2.1 The historical context of guidance development 
To review guidance for development and evaluation of complex interventions to 
improve health, I have first identified guidance models and positioned these in a 
historical timeline. The terminology used to describe complex interventions to improve 
health has changed somewhat over time. For example the term ‘health promotion’  
used in earlier work has been replaced by ‘health improvement’ or included in ‘public 
health’  in later research.21 In addition, some of the models included in this timeline 
focus on specific, aspects of intervention development and evaluation; for example a 
focus on ‘evaluability ’22 or ‘implementation fidelity.’23 However, these models have all 
contributed to the historical picture of guidance development.  
Two main approaches to early guidance development are evident from the historical 
picture. One such approach reflects the biomedical research continuum and was 
derived from pharmacological research and phased drug trials. The other main 
approach reflects a sociological perspective and was derived from sociology research 
roots. The chronological order of guidance relating to the development and evaluation 
of complex interventions to improve health is outlined in Figure 1 below. 
2.2 The biomedical research continuum 
The biomedical research continuum was summarised graphically as ‘Levy’s arrow’ in 
the 1982 publication of the director’s report to the US National Heart, Lung and Blood 
Institute (NHLBI) Advisory Council (Figure 2).24 This report was about allocation of 
research funding. Levy’s arrow outlines three progressive stages from basic research, 
via applied research and clinical trials, to provision of health services. The identification 
of a ‘Demonstration and Education Programmes’ stage between research and practice 
implementation is a strength of Levy’s arrow that has relevance for my research 
question. 
  
5 
 
Key to Figure 1 
 
Guidance derived from the bio-
medical research perspective  
Guidance derived from a 
sociological research perspective  
Guidance with a specific 
focus 
Figure 1: Historical timeline of guidance relating to the development and evaluation 
of complex interventions to improve health 
1982  US Levy’s Arrow, 1982 The biomedical research continuum (US National 
Heart, Lung and Blood Institute) 
  Flay, 1982 Phases of research in the development of health 
promotion programmes 
    
1984 US Greenwald & Cullen, 
1984 
Phases of cancer control research 
    
1998 US Nutbeam, 1998 Evaluating health promotion 
1999 US Re-AIM, 1999 Evaluating the public health impact of health 
promotion interventions 
2000 UK MRC 2000/ 
Campbell M 2000 
Framework for design and evaluation of complex 
interventions to improve health 
    
2004 UK Collins, 2004 Conceptual framework for adaptive preventive 
interventions 
 
 
UK Greenhalgh, 2004 A model of diffusion in service organisations 
2004  UK Pawson & Tilley, 
2004 
Realist evaluation 
   
2006  UK Cooksey, 2006 Pathway for translation of health research into 
healthcare improvement 
2007  UK May, 2007 Understanding the implementation of complex 
interventions in health care: the normalization process 
model 
  Campbell NC, 2007 Designing and evaluating complex interventions to 
improve health care 
2007  US Mercer, 2007 Study designs for effectiveness and translation 
research: identifying trade-offs 
  Westfall, 2007 Practice-based research – ‘Blue Highways’ on the NIH 
roadmap 
2008  UK MRC, 2008 Developing and evaluating complex interventions: new 
guidance 
2008  US Feldstein & 
Glasgow, 2008 
A practical, robust implementation and sustainability 
model (PRISM) for integrating research findings into 
practice 
2009  UK Ogilvie, 2009 A translational framework for public health research 
2010  US Breitenstein, 2010 Implementation fidelity in community based 
interventions 
 US Leviton, 2010 Evaluability assessment to improve public health 
policies, programs and practices 
2011  UK Ogilvie, 2011 Assessing the evaluability of complex public health 
interventions: five questions for researchers, funders 
and policymakers 
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Figure 2: Biomedical research continuum. US National Heart, Lung, and Blood 
institute (Levy 1982) 
 
A similar sequentially staged approach, to the development and evaluation of health 
promotion interventions, was described in influential papers by Greenwald and 
Cullen,25 Flay,26 and Nutbeam 21 in the 1980-90s. There are five stages identified by 
Greenwald and Cullen, five identified by Flay and six in the Nutbeam model. The Flay 
model distinguishes between efficacy trials, treatment effectiveness trials and 
implementation effectiveness trials. This concept of stage related summative 
evaluations is a strength of the Flay model and a recurrent theme in my thesis. The 
distinction between efficacy, described by Flay as a trial to test whether a treatment 
does more good than harm under ‘optimum conditions’ (pages 2 and 3) and 
effectiveness, described by Flay as ‘testing whether a treatment does more good than 
harm when delivered via a real-world program (page 2)’ is a useful concept for 
answering my research question. Flay goes on to distinguish between a health 
research approach to effectiveness evaluation (where efficacy has been determined) 
and a program evaluations field approach (where programmes are already operational 
irrespective of proof of efficacy). Flay stresses the importance of implementation and 
the need for ‘sequencing of studies’ (from efficacy via effectiveness to implementation 
evaluation). He explains the desirability of causal inference that can only be derived 
from experimental study designs and is also an early advocate of process evaluation. 
The Flay paper has well-defined concepts and a helpful glossary. Arguably Flay’s model 
lacks detail about developing an intervention to the point where efficacy evaluation is 
appropriate.  
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The Nutbeam model starts with ‘problem definition’ and progresses to ‘programme 
management’ with associated key research questions. The gradation from greater 
importance in assessment of outcome to greater emphasis on understanding of 
process through the stages, as shown in Figure 3, is a strength of the Nutbeam model 
and an important theme for sustainable intervention design. Nutbeam also describes 
public health outcomes and their value as judged from different perspectives and 
organisational levels (individual, community, society), which is a further strength. 
Nutbeam refers to ‘The evolution of the concept of health promotion’ (page 1) and 
highlights the importance of structure and sequence in establishing the credibility of 
health promotion.21 Arguably Nutbeam’s model lacks detail within each stage, but it is 
easy to assimilate and has proved influential. 
Figure 3: Six-stage development model for the evaluation programmes (Nutbeam 
1998) 
 
In the MRC 2000 framework, complex interventions were described as comprising, ‘a 
number of separate elements which seem essential to the proper functioning of the 
intervention’ (page 1).19 None of the preceding models (described above) are 
referenced in the MRC report or the associated British Medical Journal (BMJ) paper 
27although the staged progression paradigm is similar. The MRC 2000 framework 
distinguished five sequential stages (referred to as phases) for the evaluation of a 
complex intervention. These are: pre-clinical theory; Phase I modelling; Phase II 
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Exploratory trial; Phase III Definitive RCT; and finally; Phase IV long-term 
implementation. There is a proviso that the phases may not always be sequential, 
iteration is likely and the framework should be considered in relation to required 
evidence level and continuum of increasing evidence.19  The BMJ paper associated with 
the MRC 2000 framework includes both a linear depiction (Figure 4) and a circular 
depiction of the framework (Figure 5).27 The circular depiction is provided to 
emphasise the iterative nature of intervention development. 
In 2006 an independent review was commissioned by the UK government to advise on 
‘the best design and institutional arrangements for the public funding of health 
research.’ The resultant Cooksey 2006 report 10 presents a linear staged approach to 
intervention development and identifies two translational gaps: T1 before early clinical 
trials and T2 before health care delivery.10 A similar review was commissioned by the 
US National Institutes of Health. The US report identifies a sequence of research stages 
and similarly identifies two translational gaps.28 A third gap (dissemination and 
implementation research) was added in the ‘Blue-Highways’ paper by Westfall et al in 
2007.28 In these reports ‘gaps’ relate to research resource allocation rather than 
methodology for intervention development. 
Despite minor differences the above models all describe staged progression. These 
stages can essentially be grouped into development, testing, and implementation as 
summarised in Table 1. A three stage model fails to differentiate summative evaluation 
points usually described as efficacy, effectiveness and implementation.21, 26   In staged 
progression the starting point for effectiveness evaluation is an intervention where 
efficacy has been proven. The effectiveness problems are then about whether an 
intervention as it stands is suitable for real world settings and, if not, how it might be 
redesigned and retested.  
The appreciation that health promotion evaluation requirements are different at 
different stages of intervention development is itself an evolving knowledge base. In 
their discussion paper about choosing the most appropriate study designs and 
identifying trade-offs for assessment of effectiveness and other translational research 
evaluation , Mercer et al (2007) use a comparison chart of research stages that have 
been identified in linear progression models.29
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Figure 4: MRC 2000 framework. Sequential phases of developing randomised trials of 
complex interventions (Campbell 2000)
 
Figure 5: MRC 2000 framework. Iterative view of the development of randomised 
controlled trials of complex interventions (Campbell 2000) 
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A similar, but more extensive comparison chart of the research stages described in the 
linear models outlined here is shown in Table 1 below.  
By comparing different study designs and identifying trade-offs for evaluation 
purposes, Mercer et al explain and discuss the inevitable tension between internal and 
external validity that exists in the design of robust evaluation studies. They also point 
out difficulties in determining causality and highlight the fact that programme and 
policy decisions may often be taken irrespective of the availability of robust evidence. 
The MRC 2000 guidance 19 was acknowledged as weak on the translation from Phase 
III, ‘definitive RCT’ to Phase IV,  ‘long-term and real-life effectiveness of the 
intervention’.10  Limitations of the MRC 2000 guidance were listed in the introduction 
to the MRC 2008 guidance. There were concerns around the linearity of the clinical 
trial based model, the limited guidance on implementation phase studies, issues 
around how to tackle non-health sector interventions, and lack of attention to the 
intervention context.  
In their paper Campbell N et al (2007) discussed the MRC 2000 framework by 
considering a series of case studies and focussing on pre-trial intervention 
development. 30 The authors highlighted the MRC 2000 assertion that designing, 
describing and implementing a well-defined intervention was ‘the most challenging 
part of evaluating a complex intervention and the most frequent weakness in such 
trials.’ The authors also highlighted the need for further framework development. The 
Campbell N et al 2007 model described  two separate, but inter-related strands of 
activity, ‘optimise intervention’ and ‘optimise evaluation,’ that are required in the pre-
trial developmental stage (Figure 6). Campbell N et al advocated combining the first 
three stages (Phases (0, I, II) described in the MRC 2000 framework into one activity 
with two (intervention and evaluation) strands. They identified several ‘key tasks’ 
(centred on: problem definition, population affected, causal pathways, whether 
amenable to change, and potential for improvement) as necessary pre-trial stage 
activities. The recommendation that a decision ‘whether to proceed to a definitive 
randomised controlled trial’ has to be taken at an early stage is a strength of their 
work. There is an implication of other stages beyond the advised definitive trial. 
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Table 1: Linear progression stages  in the development and evaluation of complex interventions to improve health as identified in different models  
 Development (pre-trial) Trial evaluation Implementation 
Levy 1982 3 stages  with one divided into three smaller steps (US National Heart, Lung and Blood Institute Research Spectrum) 
 Basic and clinical research Applied research and development Demonstration and education programs 
Knowledge acquisition Knowledge validation Knowledge transfer 
 Basic research Applied research  Clinical trials Prototype studies Demonstration and education research 
Cullen 1984 5 stages (US National Cancer Institute Cancer Control Research Phases) 
 Hypothesis development Methods development Controlled intervention trials Defined population studies Demonstration and implementation 
Flay 1986 8 Stages (research pathway) 
 1Basic research 2 Hypothesis 
demonstration 
3 Pilot 
applied 
research 
4 
prototype 
evaluation  
5 Efficacy trials 6 Treatment 
effectiveness trials 
7 Implementation 
effectiveness trials 
8 Demonstration evaluations 
Nutbeam  
1998 
6 Stages of research and evaluation 
 1 Problem definition 2 Solution generation 3 Innovation testing 4 Intervention demonstration 5 Dissemination 6 Programme management 
 
MRC 2000 5 Linear stages 
 0 Theoretical  1 Modelling 2 Exploratory trial 
 
3 Definitive RCT 4 Long term implementation 
 
Cooksey 2006 9 linear stages and 2 translational gaps 
  1st translational gap  2nd translational gap  
 Basic research Prototype 
discovery and 
design 
Preclinical 
development 
Early clinical trials Late clinical trials Knowledge 
management 
Health 
technology 
assessment 
Health services 
research 
Healthcare 
delivery 
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Figure 6: Relation between context, problem definition, intervention, and evaluation 
for complex interventions (Campbell N 2007) 
 
The MRC 2008 guidance built on the MRC 2000 guidance 19 and referenced the work 
by Campbell N et al. 30 The updated guidance is introduced as providing a, ‘more 
flexible, less linear model of the process, giving due weight to the development and 
implementation phases as well as to evaluation’. 20 The MRC 2008 framework 
identified four stages with associated key functions and activities. The four stages are: 
development; feasibility and piloting; evaluation; and implementation. The MRC 2008 
guidance states that these stages may not be linear and should be interactive. This is 
similar to the approach, for the early pre-trial stage, suggested by Campbell N et al 
(2007).30 However, the concept of two parallel strands of ‘optimise intervention’ and 
‘optimise evaluation’ as discussed in the Campbell model was not included in the MRC 
2008 guidance.   
Intervention development and evaluation are closely interrelated and might be 
inextricable in the early stages of intervention development. However, for service 
provision an intervention needs to exist as an entity, separate from the research 
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paradigm where it was generated. Clearer distinction between the parallel strands of 
‘optimise intervention’ and ‘optimise evaluation’ as proposed in the Campbell 2007 
model is a useful concept.30 Failure to address this separation is a limitation of the 
MRC 2008 guidance. Similarly the concept of different summative evaluation points 
(efficacy, treatment effectiveness, and implementation effectiveness) evident in earlier 
sequential models, but not in the MRC 2008 guidance, is a limitation of MRC 2008. 
The MRC 2008 guidance 20 is written in three parts: Part I describes four main 
development and evaluation stages with associated key activities; Part II consists of 
eleven further questions (that evaluators might usefully ask themselves); and Part III 
presents a range of case studies. The four stages with their key activities are 
summarised in Figure 7 below. 
Figure 7: Key elements in the development and evaluation process (MRC 2008) 
 
 
Although the iterative nature of the development process is emphasised in the circular 
depiction of the framework the text is necessarily more sequential in its organisation. 
It is possible to map the different stages and key elements from MRC 2008 onto the 
stages as described in MRC 2000 (Table 2).19, 20  In developing a complex intervention 
the MRC 2008 guidance includes advice to, ‘begin thinking about implementation at an 
early stage in developing an intervention’ with the questions: ‘Would it be possible to 
use this?’, ‘By whom?’, ‘In what setting?, Who needs to know about the outcome?’  
‘What do they need to know?’ and, ‘What information would be persuasive?’ (Page 9)   
Although implementation to improve population health is the ultimate purpose  
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Table 2: Key-elements identified in the MRC 2008 framework mapped to the linear progression stages in the MRC 2000 framework  
MRC 2000 
5 Linear stages (Phases) 
0 Theoretical  1 Modelling 2 Exploratory trial 
 
3 Definitive RCT 4 Long term implementation 
 
MRC 2008 
Four iterative stages with associated key elements 
Development 
Identifying the evidence base 
Identifying or developing theory 
Modelling process and outcomes 
Feasibility and piloting 
Testing procedures 
Estimating recruitment and retention 
Determining sample size 
Evaluation 
Assessing effectiveness 
Understanding change processes 
Assessing cost effectiveness 
Implementation 
Dissemination 
Surveillance and monitoring 
Long term follow-up 
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behind intervention development, the fundamentally important prior requirement to 
demonstrate intervention efficacy (Does it achieve the primary outcome of interest 
under optimal conditions?), which is made clear in early models of intervention 
development has been lost in the MRC 2008 framework. There is a danger that by 
overloading early efficacy evaluation with excessive outcome and process data-
collection the opportunity to assess an optimal intervention could be buried beneath 
excessive respondent burden. Thus the opportunity to answer to the important 
question ‘Does it achieve the primary outcome of interest under optimal conditions?’ 
is lost. The need to avoid excessive respondent burden and a need to, ‘Keep it simple’ 
in designing interventions should be acknowledged in any guidance model.31  
The iterative development concept in MRC 2008 guidance means that differences in 
the outcomes that are of most relevance and value at different stages, cannot be 
teased out. For example evaluation of cost-effectiveness might be less relevant in early 
stages of intervention development, when the emphasis should be on whether the 
intervention will achieve the primary outcome of interest irrespective of detailed cost 
and benefit comparisons. That said there is an argument for modelling likely cost and 
benefit to avoid wasting resources on an impossibly high cost intervention of limited 
benefit.  
In structuring the framework around four key elements the MRC 2008 guidance draws 
an apparently simple model. However, the essence of simplicity requires sufficiently 
clear building blocks such that communication and interpretation are likely to have 
consistency. A model based on interaction of key elements and iteration is unlikely to 
achieve this. Where to start and progression order is important in any design project, 
and intervention design is not fundamentally different in this respect. The three part 
layout of the MRC 2008 guidance (Key messages (including Key elements), further 
questions, case studies), together with additional explanatory text boxes, adds further 
complexity to the guidance that makes it difficult to ensure comprehensive absorption 
of all relevant information, and thus provides opportunity for variation in 
interpretation. 
2.3 The sociological research perspective  
A different approach to design and evaluation of complex interventions was 
introduced by Glasgow et al in the RE-AIM framework(1999).32 The focus described in 
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the RE-AIM framework was on translation of research into practice, emphasising: ‘The 
reach and representativeness of both participants and settings’ (page 1322).32  This 
alternative focus was derived from sociological research roots rather than the 
biomedical perspective of the models described above. The RE-AIM authors addressed 
the need to focus on the overarching aim of population based impact of interventions 
and the importance of embedding interventions in host organisations with 
consideration of fidelity of intervention delivery and sustainability. RE-AIM uses the 
evaluation dimensions: Reach into the target population (with reference to the 
inclusion of diverse patient groups); Efficacy or effectiveness; Adoption by target 
clinicians and practice settings or institutions; and IMplementation. Implementation is 
specifically defined in this framework as comprising consistency of intervention 
delivery and maintenance of intervention effects in individuals and populations over 
time.  
Some of the evaluation dimensions in the RE-AIM framework can be mapped to 
research stages described in previous linear phased models described above, whilst 
others cannot. This raises questions around classification and highlights a need for 
consistent terminology to avoid confusion and promote effective communication. For 
example ‘reach’ cannot be described as an evaluation stage (and is unlikely to be 
confused in this respect), and ’implementation’ is used to mean different things in 
different models. 
The RE-AIM framework32 was reviewed along with other models important to 
implementing evidence based practice including the Diffusion of Innovations, 33 The 
Chronic Care model34 and Model for improvement.35 These models were assimilated to 
develop the Practical, Robust Implementation and Sustainability (PRISM) model in 
2008.36 In developing the PRISM model the authors sought to address issues of 
implementation, ‘outside the research study.’ They make the point that, ‘As long as 
efficacy and effectiveness trials are considered complete,’ [without implementation] 
their potentials are not realised.  The PRISM model aims to identify measures to 
support evaluation around how an intervention or health care programme interacts 
with its recipients and the influences of this interaction on implementation. Relative 
advantage of adopting new behaviours, from the perspectives of intervention 
recipients, is an important concept in the model alongside ensuring cultural 
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acceptability of the intervention, fit with the environmental context and adaptability to 
local settings. Activities to support implementation include: creating an infrastructure 
to encourage the spread of the intervention; addressing the barriers of frontline staff; 
linkage with service providers and users in the design stages; and leveraging 
community support. The outcome measures originating from the RE-AIM framework 
are incorporated into PRISM with the need for usefully formatted feedback reports to 
facilitate adjustments. PRISM is supported by case studies that highlight elements 
shown to affect intervention implementation and sustainability.36 
A conceptual model of determinants of diffusion of innovations in service 
organisations was derived from a systematic review and evidence synthesis of 
empirical studies by Greenhalgh et al (2004).37 In this paper the concept of ‘relative 
advantage’ is described as a ‘sine qua non’ for innovation adoption by potential users. 
This mirrors the identification of this important concept in the PRISM model. The 
Greenhalgh et al model identifies linked ‘resource’ and ‘user’ systems. The authors 
include a list of ‘innovation attributes’ that predict adoption of an innovation and 
‘system antecedents’ that affect implementation. Communication diffusion and 
dissemination pathways are included in this model.  
The focus of the Greenhalgh et al paper is on diffusion of innovations in health care 
organisations. Importantly the authors highlight the paucity of evidence around 
sustainability of innovations and suggest various areas for empirical research around 
implementing and maintaining innovations. Linkage with potential users at the 
development stage is echoed in the Greenhalgh model and described as a key activity 
that includes a concept of shared intervention development. 
The Normalization Process Model (NPM) proposed by May et al 2007 seeks to ‘Assist in 
explaining processes by which complex interventions become routinely embedded in 
health care practice.’ 38 The model identifies four influential factors: interactional 
workability, relational integration, skill-set workability, and contextual integration, 
which affect implementation of interventions. The NPM draws on sociological research 
around collective social action or group processes in the context of health care 
organisations and is principally about the behaviours of health care professionals. 
Normalization is defined as referring to the routine embedding of an innovation and is 
contrasted with ‘adoption’ where an innovation is taken up, but does not become 
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routinely embedded and ‘rejection’ where an intervention is refused (not taken up). 
The concept of ‘adoption’ in this model is therefore different from that described in 
the PRISM model. Normalization appears to be broadly equivalent to routinization in 
the Greenhalgh model. All three models, (Prism, Greenhalgh, and NPM) derive from a 
social science perspective. 
For public health interventions, implementation within a health care organisation is 
too narrow a focus and does not address potential for intervention providers to be 
different organisations, including community based organisations. Nor does the 
narrow focus on health services address the potential for collateral public health 
impact of interventions that are instigated primarily for other purposes.   
Some evaluation models derived from a social science discipline have broader 
perspectives, beyond implementation in health care. Realist evaluation as described by 
Pawson and Tilley 39 asserts that social programmes are ‘hypotheses about social 
betterment,’ or a ‘vision of change,’ thus programmes, ‘succeed or fail depending on 
the veracity of that vision.’ Pawson and Tilley describe evaluation as hypothesis testing 
that involves: formulating a hypothesis; collecting data on ‘appropriate mechanisms, 
contexts and outcomes;’ analysis of the data in relation to ‘outcome patterns to see 
which can and which cannot be explained by initial theory;’ and finally testing and 
refining the theory. All of which is a prelude to the next round of ‘ theory 
refinement.’39 How a programme might work in this model is viewed as a function of 
intervention design and its application. A distinction is made by Pawson and Tilley 
between formative and summative process evaluations. Thinking through different 
aspect s of a problem, formulating and refining plausible mechanisms for preventive 
initiatives accords with a realist approach to formative process evaluation. Collecting 
data to analyse how outcome patterns may be explained by different mechanisms in 
relation to different contexts accords with a realist approach to summative process 
evaluation. 
Process evaluation and theory testing have value in informing intervention design. 
However in interventions that are designed to improve health, the primary outcome is 
often a simple, robust and science based, health related or clinical measure. This 
outcome is beyond theory testing. What is meant by whether a programme ‘works’ 
depends on how the outcomes of interest are defined.  
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Implementation fidelity in community based interventions is addressed in a paper by 
Breitenstein et al (2010).23 Terminology is well defined in this paper with fidelity 
described as, ‘an intervention being delivered as intended by the programme 
developers and in line with the programme model.’ The authors describe two 
components of fidelity: adherence and competence. Adherence measures are of 
components specific and essential to an intervention, whereas competence relates to 
how well an intervention is delivered. Competence includes assessment of capabilities 
and skills of delivery staff. Staff selection, training, coaching, and supervision 
contribute to competence and hence to fidelity. The authors advocate clear strategies 
for fidelity monitoring and discuss available options. The tension between prescriptive 
intervention protocols and flexibility in protocol design to allow consideration of 
context and responsivity by trained delivery staff is discussed. The authors point out 
that the relationship between fidelity measures and outcome measures is under 
researched and unclear. 
2.4 Models that have a specific focus 
Work by Collins et al (2004) introduces the idea of adaptive preventive interventions 
and tailoring variables, such that the ‘dose’ of an intervention would vary with 
individual needs. This individual approach may not always be possible. The broader 
idea that intervention provision needs to be culturally acceptable is practical, and 
included in the PRISM model.36 The idea that a health promotion intervention could be 
culturally adapted has more recently been explored in an extensive Health Technology 
Assessment report.40 
Ogilvie et al (2009) proposed the ‘Translational framework for public health research’41 
that introduces a public realm ‘hub’ of media, culture, opinion, and policy. This 
framework clarifies the domain of public health as extending beyond a narrow focus 
on established systems of health care delivery. The endpoint of intervention is defined 
as improving population health. This public health domain is expanded in the UK 
Government commissioned Acheson Report as ‘The science and art of preventing 
disease, prolonging life and promoting health through organised efforts of society.’ 42 
The Acheson report references work from the nineteen twenties.43 However, linking 
population health improvement to a specific intervention provision can be 
problematic.   
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The development of this Translational framework model draws on earlier models, 
including the translational pathway in the Cooksey report.10 However, the authors 
suggest that the remit of translational public health research to be concerned with 
implementation of ‘proven’ interventions (as described in the US Centres for Disease 
Control and Prevention (CDC) roadmaps),28  is too narrow. Ogilvie et al stress the 
importance of epidemiology and the inclusion of an expanded and pivotal role for 
evidence synthesis that is not restricted to RCT evidence is a strength of this model.  
The authors also note different intervention and outcome levels (individual and 
societal) as previously described in the Nutbeam model.44  
The diagrammatic depiction of the framework is provided in a circular format shown in 
Figure 8 below. 41 This diagram is complex and arguably less amenable to consistent 
interpretation than simpler linear models. The lack of detail around intervention 
studies limits utility for intervention design, although it should be recognised that 
intervention design is not the main purpose of this model. 
 
Figure 8: Translational framework for public health research (Ogilvie 2009) 
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An ‘Evolutionary flowchart for typical complex public health interventions’ is included 
within the paper on ‘Evaluability of complex interventions’ by Ogilvie et al (2011).22 
The main focus of this paper is on five questions to assess evaluability. A further  
stated aim of this model is to, ‘better reflect the wider socio-political context in which 
complex public health interventions take place,’ thus extending the scope of 
evaluation beyond a narrow health care focus and reflecting the ‘broader focus’ 
previously explained by Ogilvie et al in 2009.  The extended vocabulary of 
implementation with broader themes including generalisability and scalability is a 
particular strength of this model. The evolutionary flowchart is shown in Figure 9 
below. 
A paradigm of circles or loops within a larger framework is clearly evident in the 
flowchart depiction. This model retains the concept of stages as envisaged in early 
linear models and uses the term ‘evolutionary’ to describe this staged progression. The 
idea of ‘key evaluable constructs’ that are particularly applicable to different 
evolutionary stages is introduced. Different outcome levels (individual, group, 
community and population) and different outcome domains (intention, behaviour, 
adiposity, health etc.) expand on the ‘valued outcomes,’ described by Nutbeam in 
1998.21 Interestingly the separation of ‘intervention’ (white boxes) and ‘key evaluable 
constructs’ (shaded boxes) as suggested by Campbell N (2007)30 is evident in this new 
framework. The distinction between process and outcome evaluation, which is a 
recurrent theme in other models, is expanded in this model. These aspects contribute 
to the utility of this evolutionary flow chart for application to intervention 
development and evaluation (although this is not the main purpose of the paper). 
The paper focusses on five questions to assess evaluability. The first question asks 
where the intervention is situated in the evolutionary flowchart of an overall 
intervention programme. However, it is not entirely clear from the example given why 
assessment of barriers and facilitators to intervention participation should precede 
evaluation of plausible health related outcomes. The second question is about the 
need to consider the effect of evaluation on policy decisions. However, this 
consideration of policy is qualified by the authors who highlight the undesirability of 
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being, ‘shackled to an excessively instrumental or pragmatic view of the value of 
research,’ thus this question is perhaps misleading at first glance.  
The third question is about possible impact of evaluation and includes reference to the 
relevance of plausible mechanisms. I suggest that, ‘Is there a plausible mechanism for 
the intervention?’ should be a key evaluability question in its own right. The starting 
point of the flow chart (concept, idea, or policy proposal) includes no explicit relation 
to scientific, aetiological or epidemiological, evolutionary roots. Thus, it is not clear 
how or where the concept, idea or policy proposal might have arisen. Epidemiology 
and knowledge of disease aetiology contribute to evaluability by providing a firm 
foundation on which intervention development and evaluation can be built.45 
The fourth evaluability question, which is about whether the evaluation would add 
value to existing scientific evidence, supports the suggestion that a scientific 
foundation for intervention development would be relevant to evaluability. The final 
question is about time constraints for the conduct of an evaluation.  This is an 
important evaluability question that reflects the tension between a need to ‘press on’ 
with intervention delivery at the expense of considered evaluation.46 
The evolutionary flowchart includes the concept of a ‘concrete’ developed 
intervention. Whereas it is true that an intervention needs to be defined precisely, for 
example in a trial protocol, for the purposes of robust evaluation, it is also true that an 
intervention is unlikely to be translated to multiple contexts without some 
modifications. For the purpose of controlled outcome evaluation a fairly precise, and 
protocol or agreement defined intervention, and a pause in intervention development 
applied at any of the evolutionary stages, might be necessary.  
Although the Ogilvie et al 2011 model is described as a flowchart it does not use 
standard flowchart decision boxes. Conventionally flowchart decision boxes are 
diamond shaped. Using a decision diamond allows one input to be related to three 
outputs. In the case of evolutionary stages of intervention development the decisions 
at each stage are dependent on the success or otherwise of the evaluation in achieving 
the outcomes of interest. Appropriate decisions might be either: proceed to the next 
stage; return to a previous stage for further intervention refinement; or do not 
proceed further. 
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It is surprising that of all these framework depictions only ‘Levy’s arrow’ employs a 
visual metaphor. 24 Metaphors can aid memorable communication in serving to 
organise and structure complex information.47 In addition, a good visual metaphor can 
convey an implicit insight by drawing on meaningful characteristics or associations that 
relate the metaphor to the information. Describing the staged approach to 
intervention development and evaluation as ‘evolutionary’ in the evolutionary 
flowchart model introduces an implied metaphor (although not visually). 
2.5 Principal findings 
In this review of guidance for the development and evaluation of complex 
interventions to improve health, I have identified two main early approaches to 
guideline development: bio-medical and sociological. The strengths of the bio-medical 
based linear continuum approach include clearly defined evolutionary stages that 
proceed from an aetiological and epidemiological scientific base where evaluation is 
centred on a clearly identified health related primary outcome. This approach has 
been limited by a focus on early intervention development stages, prior to formal 
testing, such as in a trial (efficacy), and insufficient elaboration around translation of 
trial evidence to real world settings or implementation of interventions as service 
provisions. In contrast the sociological approaches centre on theories relating to 
implementation.37, 38 Implementation in health care organisations is too narrow for 
public health interventions that may be community based, commissioned services, or 
multi-sectorial. Other guidance model approaches have been more purpose focussed, 
for example on adaptation or evaluability of interventions. Process evaluation is 
important,48 but outcome measures provide a robust evidence base for service 
provision.  
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Figure 9: Evolutionary flowchart for typical complex public health interventions 
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Separation of intervention development and evaluation strands, an appreciation of the 
difference between formative and summative evaluation, and the need for defined 
outcome measures set the scene to clarify the evolutionary summative evaluation 
points. These main summative evaluation points have been described as: efficacy (trial 
of an optimal intervention in ideal circumstances); effectiveness (trial of an 
implementable intervention in real world settings); implementation (evaluation of 
routine delivery). Further evaluation points of sustainability and population health 
impact are also relevant. I suggest that the tension between sequential and iterative 
approaches highlighted in the MRC frameworks and depicted in these and subsequent 
frameworks by using a single, circular format with bi-directional arrows, leads to 
confusion that could limit the efficient development of effective and sustainable public 
health interventions.  
However, the ‘key functions and activities’ of intervention development as listed in the 
MRC 2008 framework have provided useful detailed guidance for intervention 
development. These activities and other intervention development activities could be 
variously applicable prior to any of the summative evaluation points outlined above. 
Sequential staged evaluation points are necessarily progressive, but the processes of 
intervention development prior to efficacy evaluation, or prior to effectiveness 
evaluation have commonalities as well as differences. 
The focus in this thesis is on evidence based interventions specifically intended for 
health improvement. It should be remembered that public health policy can be 
implemented without good supporting evidence46 and collateral health benefits can 
arise from policy initiatives in other sectors. However, the link between intervention 
and its effect can be difficult to determine in these situations, which limits systematic 
intervention development and is beyond the scope of this thesis.  
2.6 Type 2 diabetes as a case study to support guideline development 
The case of T2D in relation to research model development was proposed by Narayan 
in 2004.49 In Narayan’s paper, the extension of ‘effectiveness to translational research’ 
is explained as a broader paradigm that includes sustainability, generalisability and 
transferability to the majority of people and to diverse settings. Narayan advocates the 
establishment of large multicentre studies for translation of research and introduces 
the public health orientation of optimal health care for many, within constraints of 
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cost, capacity and equity. In this model there is little detailed consideration of 
intervention development.  
Case studies have been used to support proposed guidance frameworks and analysis 
of T2D prevention has unique utility as a case study for this purpose. In the next 
chapter I describe T2D, its diagnosis, prevalence, aetiology, and associated sub-clinical 
conditions, prior to reviewing the empirical evidence for T2D prevention in individuals 
at high-risk.  
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CHAPTER THREE: TYPE 2 DIABETES 
 
3.1 Prevalence and epidemiology, increasing incidence and importance to 
world health 
Type 2 diabetes is a disease of impaired metabolism of carbohydrate, fat, and protein 
that results in hyperglycaemia.50 The prevalence of diabetes is increasing worldwide 
and it is expected to affect 438 million people by 2030.51 Diabetes is therefore a major 
world health problem. Type 2 diabetes accounts for 85% to 95% of diabetes in high 
income countries where it is now affecting increasingly younger and working-age 
adults with adverse impacts on: their life expectancy and quality of life, the duration 
and economic burden of their care, and economic productivity of their countries.51 
There is a genetic predisposition for T2D: people who have a first degree family 
member (father, mother, brother, or sister) with T2D have a five to ten times greater 
lifetime risk compared with a person with no family history.52 Presence of T2D 
associated genes and their interactions contribute to an individual’s risk profile.4 Also 
the likelihood of developing T2D is greater in certain ethnic groups, such as people of 
South Asian and African descent.53 However, T2D is essentially a lifestyle disease, 
which is associated with obesity, inactivity, unhealthy diet, urban living, and increasing 
age. 54, 55 It is a debilitating and progressive disease with specific vascular 
complications. Microvascular diseases associated with diabetes include: retinopathy, a 
disease of the eye retina that can progress from mild to proliferative retinopathy and 
may result in blindness; neuropathy, a kidney disease that can lead to kidney failure: 
and nephropathy, a nerve disease that can result in ulcerations, particularly of the 
lower limbs that may result in amputations. Diabetes is also associated with an 
increased risk of cardiovascular disease (coronary heart disease and stroke) and 
premature death.56  Diabetic complications are more likely to progress where blood 
glucose levels are poorly controlled. Diabetes related treatment cost to the NHS are 
currently estimated to be almost 8 billion per year  and these are expected to rise to 
over 15 billion by 2035 in line with increasing diabetes prevalence.57  
3.2 Aetiology and diagnosis  
 In type 2 diabetes the raised blood glucose is caused by insufficient insulin secretion, 
resistance to insulin action in the body tissues, principally muscle and liver tissues, or a 
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combination of both defects.50 58 In the early stages T2D is often asymptomatic and 
can remain undetected for years.  Type 2 diabetes is diagnosed when hyperglycaemia 
reaches a level that is associated with particularly increased risk of adverse 
pathological changes (usually referred to as ‘complications’). This level is somewhat 
arbitrary and represents a cut-point on a continuous scale. The cut-point used clinically 
has changed over time as a result of changing knowledge of the epidemiology of the 
disease and its outcomes. The trend has been towards a lower cut-point over time, 
resulting in diagnosis at an earlier stage of disease progression, which is likely to 
reduce complications and thus improve outcomes overall. 59  
The cut-points to diagnose T2D are determined from glycaemia values as surrogate 
biomarkers for the prediction of prevalent retinopathy. These cut-point values, agreed 
by an expert committee, were first published by World Health Organization (WHO) in 
1965,60 and revised in 1999.61  The WHO 1999 report includes diagnosis and 
classification of T2D based on two plasma glucose values: either fasting plasma glucose 
(FPG) or plasma glucose at two hours (2hrPG) following a standard oral glucose 
tolerance test (OGTT). 59 A standard OGTT involves ingestion of 75 grams anhydrous 
weight of glucose, usually as a glucose drink, following a fast of 10 to 12 hours. Blood is 
then drawn from the anti-cubital vein after two hours with very limited activity. The 
WHO 1999 diagnostic values are: FPG ≥ 7.0 mmol/l, and 2hrPG of ≥11.1 mmol/l 
(OGTT). Both these blood tests require a fasting test (usually self-reported) and may be 
affected by medication, test processing quality and non-adherence to fast.  
In 2011 the guidance for diagnosis of type 2 diabetes was reviewed by WHO and 
updated to include diagnosis based on the venous blood level of glycated haemoglobin 
(HbA1c).62 This type of haemoglobin provides a measure of the plasma glucose values 
over the previous eight to twelve weeks and is higher in those with hyperglycaemia.  
Diagnostic HbA1c cut-points were based on epidemiological studies of retinopathy in 
relation to HbA1c (rather than comparison with other parameters such as 2hrPG). The 
prediction of prevalent retinopathy is similar for all three glycaemia measures, 
although the optimal cut-points vary between studies.63 As a diagnostic criterion 
HbA1c has the advantage of convenience for patients as no fast is required, but it is 
affected by some haemoglobin related conditions and is not available in all countries. 
Where conditions are suitable, HbA1c has been recommended for diabetes diagnosis 
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by both WHO and the American Diabetes Association (ADA). If the HbA1c level is ≥ 48 
mmol/mol (International Federation of Clinical Chemistry (IFCC) measure, which is 
equivalent to the Diabetes Control and Complications Trial (DCCT) measure of 6.5%).64 
In the absence of clinical symptoms, diabetes diagnosis should be confirmed with a 
repeat test (Fasting Plasma Glucose (FPG, 2hrPG, or HbA1c), between one to twelve 
weeks later, preferably using the same measure.63 
Other diabetes classifications can be confused with T2D. Blood glucose tests alone will 
not differentiate between T2D and Latent Auto-immune Diabetes in Adults (LADA) or 
Maturity-Onset Diabetes of the Young (MODY).61 The distinction is important for 
appropriate treatment and there may be further sub-classifications as yet imperfectly 
determined or described.  
3.3  Risk factors and sub-clinical conditions 
Knowledge of the progressive metabolic defects preceding T2D has led to the 
identification of two WHO defined non-diabetic hyperglycaemic conditions: impaired 
fasting glucose (IFG), which is defined by WHO as a fasting plasma glucose ≥ 6.1 and < 
7.0 mmol/l (ADA ≥ 5.6 and <7.0 mmol/l), and impaired glucose tolerance (IGT), which is 
defined, by both WHO and ADA,  as fasting plasma glucose < 7.0 mmol/l and two hour 
plasma glucose ≥7.8 mmol/l and <11.1 mmol/l (FPG < 7.0 mmol/l if measured) 
following a standard OGTT.61  
3.4 Diagnostic criteria 
The criteria for diagnosis of T2D and criteria for related hyperglycaemic conditions are 
summarised in Table 3. If untreated, around 50% of people with IGT will progress to 
T2D within 10 years.65 Other risk factors for T2D are associated with IGT  including 
central obesity and dislipidaemia and IGT is a risk predictor of cardiovascular disease 
(independent of overt T2D).66 Reports of the progression from IFG to T2D are variable 
and mostly based on the earlier WHO 1985 and ADA criterion of FPG ≥ 7.8 mmol/l for 
diagnosis of T2D. 67, 68 
A number of risk scores, based on simple measures (such as family history of T2D and 
body mass index(BMI)), have been devised using cross-sectional data to screen for T2D 
prevalence.69  In addition several prospective risk scores have been devised using 
multivariate regression applied to risk parameters in cohort study data to predict 
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future development of T2D (incident T2D).70 71 One example of a prospective risk-
predictor is the Finnish diabetes risk score, FINDRISC.  This risk calculator uses simple 
non-invasive measures.72 The FINDRISC parameters are presented as categorical 
variables (with continuous variables grouped in categories where necessary), which 
means that this risk calculator can be simply completed and the risk score calculated as 
a paper exercise. 
TABLE 3: Diagnosis of diabetes mellitus and other categories of hyperglycaemia 
Modified from the WHO Consultation Report: Definition, Diagnosis and 
Classification of Diabetes Mellitus and its Complications, 1999 61 
 Plasma venous glucose a  mmol/L 
(mg/dl)  
Diabetes mellitus:  
Fasting  
2-hour post-glucose load  
 
≥7.0 (126) 
≥11.1 (200) 
Impaired glucose tolerance (IGT):  
Fasting (if measured)  
2-hour post-glucose load 
 
< 7.0 (126) 
7.8–11.0 (140–199) 
Impaired fasting glycaemia (IFG):  
Fasting  
2-hours (if measured)  
 
5.6–6.9 (100–125) 
< 7.8 (140) 
a  Corresponding values for capillary plasma differ only for the 2-hour values: for diabetes, 2 hours≥ 12.2 mmol/L (> 220 
mg/dl); for IGT, 2 hours≥ 8.9 mmol/L (≥ 160 mg/dl) and < 12.2 mmol/L (< 220 mg/dl).  
 
Recently, in the UK, a prospective T2D risk score: QDiabetes, that uses parameters 
routinely available in primary care, has been developed.73 This risk calculator uses 
categorical variables and continuous variables as appropriate and is available as an on-
line calculator. QDiabetes includes parameters for ethnicity and socio-economic status 
as well as for smoking status (these parameters are not included in FINDRISC), but 
does not include waist circumference as this is not routinely collected UK data.71  
Higher scores within prospective risk assessments may also identify prevalent T2D, 
where this is present, with varying sensitivity and specificity depending on the 
particular risk score and its parameters. Risk scores are population specific. This means 
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that a risk score that has been developed in one population cannot be assumed to be 
valid in another population. However, the progression rates from IFG and IGT to T2D 
are similarly population specific, so the determination of an individual’s risk of 
developing T2D can only be predicted with a reasonable degree of accuracy when 
suitably comparable population cohort data are available.50 
3.5  Inequality and distribution of risk factors  
The rate of conversion from dysglycaemia to T2D is different in different population 
groups. People of African-Caribbean and South Asian origin have a higher risk of 
progression and prevalence of T2D is greater in these ethnic groups.74 Prevalence of 
T2D is also socio-economically patterned.75, 76  
3.6  Diagnosis and ‘metabolic’ reversal  
Type 2 diabetes is diagnosed on the basis of sustained hyperglycaemia (with or without 
clinical symptoms) as a surrogate biomarker for microvascular and macrovascular risk. 
Therefore, T2D may be diagnosed in the absence of overt complications.61 Recent work 
has shown that, at least in the early years post diagnosis, the metabolic effects of T2D 
can be reversed by application of extreme dietary restriction, which may be associated 
with bariatric surgery.58  
Consideration of both the potential for metabolic reversal of T2D and the sub-clinical 
conditions (IGT and IFG) has led to a greater understanding of the disease 
pathogenesis.77 Where people have an inherited susceptibility to T2D, excess calorie 
intake and inactivity leads to insulin resistance in muscle tissue. The increased insulin 
secretion thus required to maintain glucose homeostasis facilitates deposition of fat in 
the liver. This ‘fatty liver’ condition causes raised plasma triglycerides and fatty-acids. 
Hyper-lipidaemia affects the pancreatic beta-cells causing cell dysfunction and reduced 
capacity for insulin secretion. The consequent inability to maintain glucose 
homeostasis and resultant hyperglycaemia, so called glucotoxicity, similarly affects the 
function of the pancreatic beta-cells. As long as the beta-cell function is recoverable, in 
the early pathogenesis of T2D, the disease may be reversed. Continued glucose and 
lipid toxicity eventually results in irreversible beta-cell damage and eventually cell 
death.  
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Liver fat is mobilised early under conditions of dietary restriction (i.e. negative energy 
balance). Consequently, extreme dietary restriction can have dramatic, almost 
immediate effects on the disease causing ‘metabolic reversal’ which may be 
permanent with continued dietary restraint. Reversing a clinical diagnosis may be 
problematic, however. The idea of intervention for disease reversal is still at an early 
stage, but it is entirely logical when the disease diagnosis rests on defined cut-points 
on a continuum of blood glucose values. Indeed, as the cut-points are defined using 
three different measures of blood glucose with or without repeat measures and/or 
clinical symptoms, there is necessarily some uncertainty around accurate diagnosis. 
However, the benefit of screening, early detection of T2D and intervention aimed at 
reduction in mortality has not been proven. 78 The development of interventions for 
primary prevention of T2D is much more advanced. 
3.7   Public health and UK context 
There is strong evidence for the effectiveness of lifestyle interventions to prevent or 
delay the onset of T2D in high risk individuals.6 The challenge is to use this research 
evidence to develop feasible, cost-effective, and sustainable interventions suitable for 
service provision. Some countries have already implemented large-scale prevention 
programmes, with various associated evaluation procedures, but the UK has only 
recently developed nationally agreed guidance. The National Institute for Health and 
Care Excellence (NICE) convened Programme Development Groups (PDG) to develop 
guidance for T2D prevention strategies for England.79 80  
The 2010 National Health Service UK (NHS) white paper describes the reorganisation of 
Public Health.81 Health Improvement is now sited within local government, where the 
local authority and their director of public health have responsibility for a budget 
(which is currently ring-fenced) that should be spent to improve health and well-being 
of the local population. Health and well-being boards, consisting of NHS 
commissioners, locally elected councillors, and patient champions, are convened to 
steer the public health agenda, as well as social care, children’s services and the wider 
work of the NHS. 
These changes in the organisation of public health services in England and the NICE 
guidance provide an opportunity for prevention of T2D in England to be developed as a 
service provision, out-with the usual clinical care pathway. For example local authority 
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leisure services may already be delivering weight management programmes and 
exercise on referral programmes. Adaptations in the design and application of these 
programmes, within leisure services, could be used to deliver lifestyle interventions 
more specifically targeted to defined outcomes including prevention of type 2 
diabetes. As general practices are already overstretched, the opportunity to utilise 
local authority leisure services or similar providers to deliver preventive interventions 
may be an attractive option for NHS commissioners. The challenge is to design 
commissionable services that are accountable, with relevant and robust outcome 
measures. 
The NHS Health Checks programme is a service for assessment of cardiovascular 
disease (CVD) risk. 82 Many of the risk variables for CVD are also T2D risk variables. 
Prospective risk scores to identify individual risk of CVD are available. The most 
commonly used CVD risk scores in the UK are the Framingham risk score83 and QRisk.84 
85 The NHS Health Checks programme86 targets adults aged 40 to 74 who are invited to 
a risk assessment appointment. During the health check appointment a patient’s blood 
pressure, blood cholesterol, smoking status, BMI and physical activity status are used 
to assess CVD risk. Recent NICE guidance advocates simultaneously assessing T2D risk 
with a risk score and a blood test alongside an NHS Health Check.9 Individuals at high 
risk may then be referred for further health care, including preventive lifestyle 
interventions. 
3.8 Summary 
The high prevalence of T2D together with knowledge of aetiology, risk-factors, 
inequalities and sub-clinical conditions provide the background for T2D prevention 
research and underlines the importance of T2D prevention for public health. In the 
next chapter, I review the extensive evidence base for T2D prevention and select 
studies that provide evidence to support different evolutionary stages of intervention 
development and evaluation: from early feasibility studies, via efficacy and 
effectiveness evaluation, to implementation.  
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CHAPTER FOUR: TYPE 2 DIABETES PREVENTION RESEARCH IN NEWCASTLE: A 
REFLECTION 
The foundation for diabetes prevention work at Newcastle University was in train 
when I joined and interventions for T2D prevention in Newcastle have developed in 
parallel with preventive initiatives elsewhere. I have been privileged to have had 
excellent opportunities and considerable autonomy to contribute to and drive forward 
this valuable work. Along the way I have developed research skills, refined and 
expanded my collaboration and communication skills and worked through practical 
problems and solutions. The experience and insight gained from working in diabetes 
prevention over a number of years has provided the foundation for my thesis and this 
chapter tells the story of my work, from my own perspective.  By relating this story 
chronologically, I have shown how my thoughts and ideas have developed. This history 
also provides the context for the published papers included in this thesis.  
4.1 Background 
The Newcastle Heart Project (NHP),87 which was a cross-sectional study of risk factors 
for cardiovascular disease and T2D in different ethnic groups in the North East of 
England, provided the epidemiological basis for subsequent preventive research. This 
study demonstrated differential risk of T2D and cardiovascular disease for different 
ethnic groups and thus raised issues regarding equity for design of preventive 
interventions. The Newcastle IGT study tested the feasibility of lifestyle intervention, 
where participants were white European adults with IGT.88 This study had improved 
glycaemic control as a primary outcome and acted as a pilot for EDIPS locally. The 
intervention delivery strategy, eventually used in the Newcastle arm of EDIPS derived 
from the Newcastle IGT study. EDIPS Newcastle, built on the Newcastle IGT study, with 
T2D incidence as a primary outcome.89 The EDIPS collaboration was co-ordinated from 
Helsinki in Finland. The studies in this collaboration had a common protocol to 
facilitate data collation. There were also common intervention goals, but some 
flexibility in intervention delivery. 
4.2 European Diabetes Prevention Study 
When I joined Newcastle University as a Junior Research Associate, the EDIPS-
Newcastle RCT was part way through recruiting participants. To complete the 
recruitment I engaged local primary care practices where practitioners identified 
adults likely to be at risk of future T2D by searching their practice databases for 
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patients with risk factors, including hypertension (Blood pressure 160/90 mmHg), 
overweight or obesity (BMI ≥ 25 kgm-2 ), and family history of T2D. I then worked with 
the practice to invite people with risk factors to come to the Royal Victoria Infirmary in 
Newcastle for assessment. The assessment included an OGTT and those who were 
identified with IGT on this first screening were invited for a second OGTT to determine 
persistent IGT. People diagnosed with T2D were excluded from the study and their 
primary care physician was informed. 
The primary outcome of the EDIPS-Newcastle intervention was T2D incidence. The risk 
reduction in the intervention group compared with the control group was 55%, (RR 
0.45, 95% CI 0.2 to 1.2), which was similar to the 58% risk reduction (HR 0.4, 95% CI 0.3 
to 0.7; p<0.001) demonstrated in the Finnish DPS. Analyses of EDIPS-Newcastle 
primary and secondary outcomes were published in my first submitted paper.11 
SP1. Prevention of type 2 diabetes in adults with impaired glucose tolerance: the 
European Diabetes Prevention RCT in Newcastle upon Tyne, UK Penn L, White M, 
Oldroyd J, Walker M, Alberti KGMM, Mathers JC: BMC Public Health 2009; 9(1): 342  
The flow-chart in this paper outlines the recruitment procedure, which indicates that 
identification of persistent IGT was time consuming and burdensome. The flow-chart 
should make this difficulty clear, but actually doing the assessment work has greater 
personal impact and I appreciated the problems of persistent IGT as a recruitment 
criterion (e.g. number needed to test, variability of IGT between sequential tests). By 
the time the EDIPS-Newcastle results were ready for publication both the DPS and DPP 
had already published their outcomes. 12, 90  Therefore we knew that additional 
analyses would improve the paper and its publication potential. Whilst working on the 
EDIPS-Newcastle I completed a qualitative study associated with the Newcastle-EDIPS, 
relating to participants’ perspectives on maintaining behaviour change, which was 
subsequently published (not included here as this publication resulted from previously 
examined work).18 Partly through this qualitative work I developed an additional 
analysis plan for secondary outcomes from the EDIPS-Newcastle. The underpinning 
behaviour change theory for EDIPS-Newcastle was the Transtheoretical Model. 
Motivational interviewing techniques were of key importance to the individualised 
intervention delivery strategy. Sometimes I sat-in on the consultations when the 
dietician and / or physiotherapist who delivered the intervention were counselling 
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participants. A tenet of motivational interviewing is about enabling people to plan 
their own individual actions and set goals for themselves. Through listening to the 
dietician I appreciated that there was clearly a conflict between motivational 
interviewing techniques and externally set goals (e.g. for weight loss targets of 5% as 
advised in the EDIPS-protocol). I also appreciated that maintenance of lifestyle change 
was a particularly important feature of this prolonged intervention. These ideas helped 
to formulate additional analysis for the first EDIPS-Newcastle paper.  I designed and 
conducted an explanatory analysis of EDIPS-Newcastle data to assess beneficial change 
of any magnitude, which was maintained for two or more years, in the secondary 
outcome measures (weight loss, increased physical activity, reduced percentage 
dietary fat intake, increased percentage carbohydrate intake, and increased dietary 
fibre intake). This ‘direction of change’ analysis within the EDIPS-Newcastle data was 
designed to assess whether small beneficial changes that were maintained would be 
important for T2D prevention. The analysis suggested that this was likely, but the small 
sample size of the Newcastle data-set alone was a limitation for conclusive analyses. 
In conducting the EDIPS-Newcastle trial I began to question the use of 2hrPG for 
assessment of an individual’s ability to cope with a glucose challenge, which is the 
rationale for determining IGT. During the assessments I collected blood samples at 
baseline, 30, 60 and 120 minutes after ingestion of an OGTT load. I processed these 
samples during the same morning. There had been some research on the shape of the 
OGTT curve that provided evidence to support my hypothesis that the one hour 
plasma glucose would be a better proxy than 2hrPG for estimating the area under the 
OGTT curve. My interest in one hour glucose provided impetus for my pro-active effort 
in the collation of the full EDIPS data set. On its own the EDIPS-Newcastle dataset was 
too small for meaningful secondary data analysis. Collation of the EDIPS data was 
planned from the start of the EDIPS-Newcastle study, but as the DPS results were 
already published, and as the EDIPS collaboration was less extensive than was 
originally envisaged, the will to complete the data collation could have foundered.   
I prepared a synopsis, based on various biomarkers for prediction of T2D with a 
preliminary analysis using the EDIPS-Newcastle data-set to demonstrate the potential 
for this exploratory analysis in the collated data and sent it to the EDIPS co-ordinating 
team in Finland. We were able to discuss this and other analyses that might be 
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possible with collated EDIPS data during the 5th World Conference for Prevention of 
Diabetes in Helsinki in 2008. Nevertheless it took a long time and much effort for the 
data from Finland, The Netherlands and our own work from the UK to be collated, 
checked and distributed to each of the three collaborating centres. We agreed the 
method for this in principle during a meeting in Helsinki in November 2008. During this 
meeting we also allotted leadership for various possible secondary analyses (brief 
outlines). To facilitate collation of the EDIPS data I prepared the common data 
template as an SPSS file and supplied the EDIPS-Newcastle data. The data from 
Maastricht were supplied using my template by Annemieke den Boer, the work of 
putting the three EDIPS files together was mostly done by Jaana Lindström in Helsinki, 
and the three of us checked the data. 
 After the EDIPS data had been collated, checked and distributed I was offered the 
opportunity to draft a paper reporting the analysis of the EDIPS primary outcome: 
effect of lifestyle intervention on incidence of T2D, thus giving Newcastle the lead on 
this paper. By this time a number of RCTs had already been published demonstrating 
the preventive effect of lifestyle intervention and there was also review level evidence. 
The EDIPS primary outcome was therefore not novel. However, I was appointed to 
serve as a professional member of the NICE Programme Development Group (PDG) for 
NICE guidance on ‘Prevention of type 2 diabetes: risk identification and intervention 
for individuals at high-risk.’ I used information and ideas gained through this 
experience to formulate additional analyses for the EDIPS paper. (SP2) Essentially the 
explanatory analysis in this paper is about how efficacy research might be revisited to 
evaluate evidence based guidance. Working with the NICE guidance team as a member 
of the PDG was an intense experience. Even though the evidence base for T2D 
prevention is extensive, research evidence is not guidance. The focus on producing 
‘evidence based’ guidance from the available evidence was salutary. It was also 
illuminating to hear how group members reflected their own perspectives within the 
group, which could lead to controversy and engendered very thoughtful discussion. 
The details of NICE PDG discussions are confidential within the group, but I believe I 
made a valuable and influential contribution. 
The first analysis of the collated EDIPS data is the subject of my second submitted 
paper. 
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SP2.  Weight loss in prevention of type 2 diabetes in adults with impaired glucose 
tolerance: the European Diabetes Prevention Study RCT, L Penn, M White, J 
Lindstrom, A den Boer, E Blaak, J G. Eriksson, E Feskens, P Ilanne-Parikka, S M 
Keinänen-Kiukaanniemi, M Walker, J C Mathers, M Uusitupa, J Tuomilehto. PLoS ONE 
2013;8(2)  
Analysis of the EDIPS primary outcome, T2D incidence, makes a contribution to the 
evidence for diabetes prevention and extends this to three European populations. I 
sought to add value to this publication by including an analysis based on achievement 
and maintenance of the 5% weight loss goal advocated in the EDIPS protocol and in 
NICE guidance. In planning this explanatory analysis I was aware that it would inform 
further development of translational diabetes prevention studies.  I also designed and 
conducted analyses of T2D incidence in EDIPS sub-sets defined by baseline blood 
parameter ranges for FPG and HbA1c. These hyperglycaemia measures are more 
convenient than IGT for risk assessment and thus might be considered more suitable 
as inclusion criteria for translational studies. The NICE guidance advocated a risk score 
assessment followed by a blood test (FPG or HbA1c) with specific cut-points to identify 
individuals at high-risk for the application of preventive intervention, but the evidence 
for effective prevention of T2D is from populations where high-risk is defined by IGT. I 
maintain that this extrapolation of evidence beyond the population where the 
evidence was generated is a significant weakness in the NICE guidance.  
Although the EDIPS interventions were successful in demonstrating the efficacy of 
lifestyle interventions in reducing T2D incidence there were some individual 
participants, in both the intervention and control groups, who were diagnosed with 
T2D very early in the trials. As the changes advocated in the intervention involved diet 
and physical activity modifications it is possible that these may have taken some time 
to implement. Also, although the EDIPS intervention was intensive, in terms of number 
of contact occasions, the beneficial lifestyle changes advocated were quite modest. 
Consequently I began to consider whether a variation in these targets, such as for 
more extreme and immediate lifestyle change, might be more appropriate for people 
at imminent risk of T2D, ( i.e. those highly likely to develop T2D within one or two 
years). 
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Recent work has shown that, at least in the early stages, T2D can be reversed by 
extreme dietary restriction.58  There may therefore be a value in distinguishing 
different risk groups within the progression of hyperglycaemia, for example 
differentiating those with a T2D risk probability of 50% ten years from those with a 
T2D risk probability of 50% in two years. 
The most pressing need and greatest contribution for health improvement in the 
population at risk is for the effective and sustainable translation of interventions for 
prevention of T2D to real world settings. However, this should not preclude the 
continuing quest for greater scientific understanding of the underlying mechanisms 
and aetiology (through epidemiology, biochemistry, physiology or systems biology), of 
progression to T2D. This knowledge will continually progress theory based possibilities 
for intervention improvement.  
An interest in the potential to identify those people at imminent risk of T2D and the 
potential utility of the one hour plasma glucose parameter led to an analysis of bio-
marker predictors in the collated EDIPS data set, which is being prepared for 
publication. 
4.3 European Nutrigenomics Organisation 
Following completion of the EDIPS-Newcastle trial I took the opportunity to work with 
the Newcastle Work-Package (WP6 Human Studies) of the European Nutrigenomics 
Organisation (NuGO). The work encompassed by NuGO was mostly lab-based, but the 
human studies work package included study design and ethics where I contributed to 
discussions. This was an interesting and productive learning experience that 
broadened my knowledge and linked my current work to my original interest in 
physiology and biochemistry, which was the subject area of my BSc. Within weeks of 
starting this work I had collected pages of new vocabulary around ‘omics’ techniques 
all of which makes reading papers relevant to my current work that include this 
terminology more accessible. During the NuGO programme I helped to organise a 
workshop on ‘Design of human nutrigenomics studies’ and two workshops on 
assessment of dietary intake. I have included a published report from one of these, 
where I was first author, as supporting documentation.91  
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Of particular immediate interest for assessment of dietary intake in translational 
studies is the potential to use Multiple Source Methods (use of 24 hour recall together 
with population level food frequency questionnaires). Through the EDIPS-Newcastle 
work I was very aware of the respondent burden imposed by the completion of three 
day food diaries, which was the dietary data collection method in this protocol. Not 
only did we have missing data, where people had failed to complete food diaries at all, 
but the quality with which these were completed was variable and in many cases the 
completion quality ‘tailed off’ markedly after the first day. Dietary assessment is 
notoriously difficult and the respondent burden is a particularly important 
consideration for translational studies and applying an intervention to people with low 
literacy or where there are language issues. 
An objective measure of dietary intake, as has been evaluated in small scale 
metabolomics studies, would be useful. From the information provided to the 
workshop I thought the possibility that urine pH (acidity) might be used to assess 
intake of fruit and vegetables had interesting possibilities. This measure has been used 
in population cohort studies, but had not been used to assess change in intervention 
studies. My suggestion (to use urine pH to assess change in dietary intake of fruit and 
vegetables) has subsequently been included in an on-going project at Newcastle 
assessing the relationship between blood pressure and intake of fruit and vegetables 
(VegBP), which is currently underway. Depending on the outcomes there could be 
potential to progress this. 
SD1. Assessment of dietary intake: NuGO symposium report. Linda Penn, Heiner 
Boeing, Carol J. Boushey, Lars Ove Dragsted, Jim Kaput, Augustin Scalbert, Ailsa A. 
Welch and John C. Mathers, Genes & Nutrition, 2010. 5(3): p. 205-213.  
4.4 The ‘New life New you’ translational intervention 
In 2008 an opportunity came about, through the ‘legacy’ requirement associated with 
the London 2012 Olympic and Paralympic Games.  Integral to the bid for the London 
Games was the aspiration that the Games would support and inspire more people in 
the UK to enjoy sport and physical activity. In the North East of England part of the 
local ‘2012 Nations and Regions Group’ remit was to address local contributions to this 
aspiration and ‘unlock sustainable regional benefits’ including in the area of health and 
physical activity.  An expert steering group, with representation from Sport England, 
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local government, the NHS, Diabetes UK and Newcastle University was convened to 
consider options.  This group proposed an outline plan for the development and pilot 
evaluation of a community based intervention for prevention of T2D in adults at risk, 
with the potential to implement a pragmatic T2D prevention intervention across the 
North East region, with a particular focus on communities most in need. The outline 
proposal was for an intervention to be led by fitness trainers in local authority leisure 
and community settings in a North East area with high levels of socio-economic 
deprivation, where there was likely to be a high prevalence of adults at risk of future 
T2D.  The cross-sector approach, bringing together health and leisure sectors in 
partnership, was in line with the contemporary national policy and regional strategy.  
The outline structure of the intervention and the decision to inculcate robust 
evaluation procedures from the start of the intervention development was determined 
by the steering group. I then had the opportunity to work with the intervention 
delivery team to develop this intervention pilot and, as I had just completed the EDIPS-
Newcastle trial, this was timely. 
At the time I had just completed a systematic review for the BMJ Health Intelligence 
web site so I was able to use this evidence review in planning the intervention. 
Although this website no longer exists, I have included the text we supplied to the BMJ 
as supporting documentation. 
SD1. BMJ Intelligence: Public Health Evidence section: Prevention of type 2 diabetes 
Penn L, White M. 2006  (Website no longer accessible) 
The systematic searches for identification of IGT that were provided by the BMJ team 
for this review did not include a risk score tool. However, after visiting Finland for a 
conference associated with the FIN-D2D translational study I appreciated the utility of 
risk scores. I learnt the difference between a prospective risk score for future T2D (that 
could therefore be used as a proxy to identify IGT), developed from cohort study data, 
and prevalence T2D risk score, developed from cross-sectional data. We secured 
agreement to include FINDRISC within the BMJ review. This important quality 
distinction between a risk score derived from cohort data and a cross-sectional score 
has been highlighted in a recent review paper 92 and risk scores compared in another 
recent paper.71 This risk-score method for identification of individuals at high-risk was 
42 
 
vital for the development of the NLNY pilot where there was no provision for blood 
testing and using an OGTT would be impractical.  
In developing the NLNY intervention the small fieldwork team had considerable 
autonomy within the outline structure. There were many challenges and compromises, 
but the desire to realise a workable intervention design with embedded evaluation, 
together with mutual respect for each other’s professionalism and differing expertise 
allowed tensions to be resolved within this small team. I believe this model, which 
allowed collaborative operational optimisation of the intervention, offered an ideal 
solution and provides lessons for translational research more generally. Even when an 
intervention has been shown to be effective in one setting, the application to a 
different context requires thorough piloting. 
Details of the translation process are provided in the chapter entitled ‘Towards the 
translation of research evidence to service provision: experience from North East 
England, UK’ in the book published for the World Conference for Prevention of 
Diabetes held in Dresden, Germany in 2010.  I was invited to submit a chapter and I 
chose to report on both the EDIPS-Newcastle and the ‘New life, New you’ pilot study. I 
explained ways in which the evaluation procedures and requirements in the 
translational study were informed by and differed from the trial evaluation 
procedures. I have included this book chapter as a supporting document.  
SD2. Towards the translation of research evidence to service provision: experience 
from North East England, UK. Penn L, Lordon J, Lowry R, Mathers JC, Smith W, Walker 
M, White M.  in Diabetes Prevention in Practice, Peter Schwarz, Editor. 2010: Dresden.  
Following the conference I was invited to revise this chapter for publication in a special 
edition of the British Journal of Diabetes and Vascular Disease focussing on prevention 
of T2D. At this time I was able to include results from the NLNY pilot study first cohort 
at six-months. The resulting publication is my fourth submitted paper. 
SP3.  Translating research evidence to service provision for prevention of type 2 
diabetes: development and early outcomes of the ‘New life, New you’ intervention. 
Penn L, Lordon J, Lowry R, Mathers J, Smith W, Walker M, White M. Br J Diabetes 
Vasc Dis 2011;11:175-181  
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Consideration of the translational process at a local level and an appreciation of 
differing evaluation requirements through different phases of intervention 
development set the seed for the wider consideration of this process, within diabetes 
prevention interventions, which is the overall theme of my thesis. 
As a feasibility study NLNY cannot provide robust evidence of effectiveness. However it 
proved timely for the NICE Programme Development Group and the subsequent 
guidance for diabetes prevention. 93 The NLNY intervention is also of current interest 
because it has been designed as a health and sports (leisure service) partnership. 
Health promotion services have been transferred to Local Authorities as part of the 
reorganisation of the NHS and pPublic Health resulting from the Health and Social Care 
Act, 2012. 94 The NLNY outcomes at one year are the subject of my fourth submitted 
paper.13 
SP4.  Feasibility, acceptability, and outcomes at 12 months follow-up of a novel 
community based intervention to prevent type 2 diabetes in adults at high risk: 
mixed methods pilot study.  Penn L, Ryan V, White M. BMJ Open 2013; 3(11). 
In this study, 218 participants were recruited to the intensive lifestyle programme. 
Follow-up at 12 months was completed by 134 (61%) participants. Estimated mean 
(95% CI) changes from baseline were:  weight -5.7 (-7.8 to -2.8); -2.8 (-3.8 to -1.9)kg, 
waist circumference -7.2 (-9.2 to -5.2); -6.0 (-7.1 to -5.0) cm, and PA level 7.9 (5.8 to 
10.1); 6.7 (5.2 to 8.2) MET-hours per day equivalent, for men and women respectively 
(from covariance pattern mixed models). Participants’ reported an enjoyable, sociable, 
and supportive intervention experience. The high retention and positive outcomes at 
12 months follow-up, were encouraging indicators of acceptability and likely 
effectiveness. 
The qualitative study associated with the EDIPS-Newcastle trial provided evidence to 
underpin the development of the NLNY study and is cited in the NICE-R4.9 Before NLNY 
started the project team commissioned social-marketing consultations with key 
stakeholders; both prospective staff and participants. The social marketing reports 
identified participant preference for single sex activity sessions and the importance of 
seamless access to the intervention.  When the first NLNY cohort had completed one 
year in the study, I was able to plan some more formal in-depth qualitative research. 
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The topic guide for this built on the work I had done for the EDIPS-Newcastle 
qualitative study and also took advantage of more recent work relating to behaviour 
change strategies. Following discussion with co-authors, I used the refined Theoretical 
Domains Framework for behaviour change to categorise themes emerging from the 
qualitative data.95, 96 In the early stages of intervention design we actively planned to 
use the social potential of physical activity sessions to promote engagement with the 
intervention. The qualitative analysis, together with experience from the feasibility 
study, has contributed to intervention refinement. The importance of social factors in 
promoting intervention recruitment and retention, and social support for maintaining 
behaviour change post intervention were important findings from this qualitative 
research. The publication resulting from this qualitative evaluation is my fifth 
submitted paper. 17  
SP6.   Participants’ perspectives on making and maintaining behavioural changes in a 
lifestyle intervention for type 2 diabetes prevention: a qualitative study using the 
theory domain framework. Penn L, Dombrowski SU, Sniehotta FF, White M. BMJ Open 
2013;3 (6)  
This qualitative evaluation contributed to the acceptability assessment of the NLNY 
intervention and highlighted intervention features that promoted recruitment, 
retention in the intervention and maintenance of behaviour change after the follow-
up. Social influences, and intentions and goals were dominant themes in all phases of 
behaviour change. The environmental context and resources were reported as 
important for the intervention participants, as was anticipated for this community 
from an area of social deprivation. 
4.5 Impact of organisational changes  
Following the NLNY feasibility study there was a period of funding insecurity. The 
trainers were unable to guarantee a full intervention programme to new recruits. 
There were also difficulties because some ‘original’ participants, recruited early in the 
programme failed to move on to more independent physical activity and were still 
accessing NLNY sessions. In response the trainers deviated from the original protocol, 
which was that all new recruits would receive a 10 week programme, and began 
integrating new recruits into existing sessions. The consequence was fewer new 
recruits and continuing difficulties where people failed to exit the programme. 
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Although entirely unplanned this has proved very useful for the future in underlining 
the need for clear fidelity monitoring and explicit guidance.  
4.6 New Life New you service level agreement 
Following the NLNY pilot study and the period of funding insecurity, I worked closely 
with both the local NHS commissioning team and the trainers to develop a written 
contractual ‘Service Level Agreement’ (SLA) for the commissioning of the NLNY 
intervention as a service provision in the local area where it was piloted. I used the 
analyses from the first two cohorts of the pilot study to supply realistic ‘Key 
Performance Indicators’ (KPIs) that have been included in the SLA. Additional KPIs will 
be incorporated as further data become available. I also wrote a detailed intervention 
manual that includes the relevant NICE guidance. 
The fact that some people tended to stay involved with the NLNY programme even 
when their year was complete was inconvenient for the smooth running of 
recruitment and progression, but it was also testament to the quality of the 
intervention delivery. The qualitative work helped in understanding and promoting the 
potential of a peer-support role for participants who, having completed the NLNY 
intervention might be able to volunteer their time and commitment to helping new 
recruits who had recently completed their 10 week programme. Requirements relating 
to the enrolment and training of community members are included in the SLA. We 
have identified possible roles for community member as ‘awareness champions,’ to 
promote recruitment to the programme and as ‘peer-supporters’ to encourage 
continued engagement with the programme. 
The administration of the NLNY intervention, to ensure accurate and relevant data 
collection, was a challenge for the fitness trainers in the early days. I worked with our 
database designer to plan the first database. This database has now been revised to 
automatically generate the KPI service monitoring reports that are required as part of 
the SLA. I have also prepared web-access forms for additional data input. This dual 
input approach both simplifies the database and provides an accuracy check. 
 
The DPP based studies (e.g. the DEPLOY study) access a protocol with detailed session 
plans.97, 98 This ‘top down’ detailed approach might be appropriate when intervention 
adherence is considered the most important intervention feature, and it may have 
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utility where the delivery staffs are minimally trained. However the NLNY fitness 
trainers were experienced professionals and from the start of intervention 
development they rejected this degree of prescription, citing their previous experience 
with similarly prescriptive weight management programmes. Also the NLNY 
intervention, which relied on a novel ‘do and reflect’ model, would not accommodate 
this degree of session detail. The activities provided needed to be resource compatible 
and responsive to participant preferences. The development of KPIs as part of the SLA 
allowed flexibility in delivery and will be evaluated in the next phase of the local 
service implementation. 
4.7 Adaptation of the New life, New you intervention for ethnic minority 
groups 
The NLNY intervention has been extended and adapted to be more engaging and 
appropriate for individuals at high-risk within local ethnic minority communities. The 
intervention delivery for women is being conducted by a community provider where 
the lead fitness instructor is from the local South Asian (SA) ethnic community. This 
model for intervention provision is described as a ‘Community Interest’ model, which 
is a not-for-profit business model. As a result of the rapid recruitment of women to this 
adaptation of the NLNY intervention the community provider has recruited other 
women from the local ethnic community as trainers. The local NHS health 
improvement service has provided funding support so that these SA women can 
receive basic training, through a Register of Exercise Professionals (REPS) accredited 
provider, as health and fitness trainers, to allow them to deliver the NLNY intervention. 
These newly qualified trainers then work with a more experienced trainer. This co-
working is an important continuation of their training that ensures the quality and 
supportive ethos of the programme is maintained. These trainers work on a casual, 
session by session basis and are therefore paid solely for the hours they work. This 
community interest model therefore epitomises a vision for the way peer supporters 
might become incorporated. The NLNY adapted provision for men from the local 
ethnic minority community has been slower to progress. 
I took advantage of the rapid and successful expansion of the ethnic adaptation of the 
NLNY programme to conduct qualitative interview studies with the SA women 
participants and the newly qualified trainers. This was an excellent opportunity for 
some interesting work that will help to elicit participant perspectives and further 
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consider the potential of this intervention delivery model. We also plan to evaluate the 
feasibility, acceptability and outcomes at 6 and 12 months follow-up of the adapted 
intervention.  
A necessary part of this NLNY adaptation for the local ethnic community is a widening 
of the age range for recruitment, in line with recent NICE guidance for communities at 
risk. As the NICE guidance applies to risk factor assessment in people of all ethnicities, 
this extension in age will be similarly applicable to the whole NLNY recruitment cohort. 
The intervention design which allows for grouping of ‘like-minded’ participants 
facilitates the grouping by age, ethnicity, and /or sex as required by the participants 
and as considered appropriate by the intervention providers.  
4.8 Current and future plans 
The recruitment and retention success of the NLNY model has resulted in pressure, 
from maternity services, to incorporate provision for women who have had gestational 
diabetes. Interestingly the original Wien study was conducted in women with previous 
gestational diabetes and with current IGT, thus efficacy of preventive intervention is 
this high-risk group has been tested.99 Recent qualitative work by Lie et al100 has 
explored the feasibility of preventive intervention for this population and uncovered 
important contextual factors.  Current plans for the NLNY local provision are to include 
gestational diabetes as a single risk criterion for recruitment and this variation in 
recruitment will be evaluated separately. Design of a specifically tailored adaptation of 
NLNY is a future option. 
4.9 Summary 
Review and analysis of the guidance literature and review and analysis of the T2D 
prevention literature are no substitute for day to day experience of working to 
progress intervention development and evaluation in the field, but these three strands 
of knowledge are complementary.101 In relation to my research question the most 
novel contribution of my empirical work is regarding the implementation stage of the 
evolutionary progression in intervention development. The implementation stage is 
where the literature is most scarce and where context becomes increasingly relevant. 
The options for service provision are necessarily different in different health care and 
public health contexts. An implementation strategy that works in one country is not 
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necessarily transferable to another, although lessons can be learnt from different 
experiences.102  
My research publications in support of my thesis are included in appendices A to E 
starting on page 95 and it may be appropriate to read these papers at this point. In the 
next chapter I review the wider literature relating to T2D prevention. 
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CHAPTER FIVE: LITERATURE REVIEW AND SELECTION OF TYPE 2 DIABETES 
PREVENTION CASE STUDIES 
 
5.1 Sources of evidence 
This literature review is restricted to lifestyle interventions for individuals at high risk 
of future T2D, since that has been the focus of my work. It is not a standard systematic 
review. Extensive systematic reviews of T2D prevention literature have been 
completed recently,9  It would not be appropriate to repeat these. Instead I have used 
a purposive approach to identify T2D prevention studies for high-risk individuals that 
provide evidence spanning different evolutionary stages in intervention development 
and evaluation. For my literature review I have drawn on: 
 Four recent NICE systematic reviews:9  
 A previous T2D prevention literature review that I co-authored for the British 
Medical Journal, ‘Public Health Intelligence’ web site (which is unfortunately no 
longer available online),89  
 The Diabetes in Europe – Prevention using Lifestyle, Physical Activity and 
Nutritional intervention (DE-PLAN) final report, and publications, including 
chapters from the book produced for the World Conference for Prevention of 
type 2 diabetes in 2010.103-105  
5.1.1  NICE reviews 
The NICE public health guidance for T2D prevention was split into two: the first 
guidance for ‘Population and community interventions,’ was published in May 2011,80 
and the second for, ‘Risk identification and interventions for individuals at high risk,’ 
was published in July 2012.9  The second guidance is most relevant to my thesis. 
To inform the second guidance, NICE commissioned four systematic literature reviews, 
all of which were conducted by the University of Sheffield, Public Health Collaborating 
Centre at the School for Health and Related Research (ScHARR).9 The first of these 
(NICE-R1) was ‘Identification and Risk Assessment of adults with pre-diabetes,’ the 
second (NICE-R2) was a ‘Systematic review and meta-analysis of lifestyle, 
pharmacological and surgical interventions’ and is restricted to RCT evidence, the third 
(NICE-R3) was of, ‘Mechanisms of successful interventions and translation of major 
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trial evidence to practice,’ and the fourth (NICE-R4) reviewed ‘ Barriers and facilitators 
affecting the implementation and effectiveness of interventions to assess the risk of 
progression to diabetes, and the implementation of preventive interventions and 
behaviour change’. 
Strengths: The NICE reviews were systematic, comprehensive within the scope of the 
guidance, good quality and up to date (guidance published July 2012, reviews from 
2011). Included studies were quality assessed using Jadad106 scores and NICE checklist 
scoring system.9  
Limitations: During the process of guideline development the title of the NICE guidance 
was changed. However, the reviews reflected the original title which was: Preventing 
the progression of pre-diabetes to type 2 diabetes in adults. This focus on pre-diabetes 
was a limitation, both for the conduct of all the reviews and for the development of 
the NICE guidance. Effectively by limiting high-risk to ‘pre-diabetes’, NICE had pre-
judged the most appropriate risk assessment procedure that is pertinent for 
translational interventions and thus excluded a body of relevant evidence.107  
Jadad scoring for quality assessment relies on features of randomisation.108 One of the 
three Jadad questions: ‘Was the study double blind?’ is not appropriate for lifestyle 
intervention studies, which limits the contextual utility of this quality assessment. 
5.1.2  BMJ Health intelligence 
Our review for BMJ Health Intelligence (2008) included four sections: 1a on 
interventions that aim to prevent or delay the onset of T2D in adults with IGT, 1b cost 
considerations for 1a, 2a identifying adults with IGT, and 2b cost considerations for 2a. 
(The web-site text is submitted as supporting documentation SD1 in Appendix A. This 
web-site is no longer accessible) 
Strengths: The searches were conducted systematically by the BMJ team who supplied 
a list of papers to review. For each study we prepared a short ‘fact file’ with the title 
and answers to the questions: What is it? Does it work?  How does it work? Does it 
only work in certain groups of people? This unusual ‘fact file’ format was specifically 
requested by the BMJ team to answer key assessment questions. This review also 
included papers that reported secondary analyses associated with the main prevention 
trials.109-111  
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Limitations: Intervention studies were restricted to review level and RCT evidence in 
adults with IGT and the time span of search was limited to 2000 -2007. 
5.1.3  DE-PLAN report and publications 
Following the completion of the Finnish DPS, a large multicentre European project: 
Diabetes Prevention in Europe (DE-PLAN)107 was introduced and funded by the 
European Commission public health 5th Framework. The objectives for the DE-PLAN 
project were to: ‘assess the T2D risk in European populations and implement and 
evaluate a lifestyle intervention programme to prevent T2D in high-risk individuals.’72 
The DE-PLAN project involved diabetes prevention interventions conducted in 17 
European countries (21 partner centres and 4 collaborating centres) between 2005 
and 2008 (Figure 9). These studies were not included in the NICE translational studies 
review as they did not recruit participants with ‘pre-diabetes’. 
Strengths: The DE-PLAN programme aimed to address the development of national 
community-based T2D prevention programmes systematically throughout European 
countries.  
Limitations: Most of the DE-PLAN studies were conducted with a relatively weak 
before-and after study design and there are few publications to my knowledge (to 
date) in peer-reviewed journals. 
5.2 Study selection criteria 
The term ‘evolution’ Nutbeam 1999 (page 41) or ‘evolutionary’ Ogilvie et al (2011), to 
describe the progression in  development and evaluation of complex interventions is 
useful to clarify an assumption that each stage should add evidence that will inform 
the next stage.   
In reviewing the literature, I have selected studies for analysis using the criterion: 
Does this study provide evidence to support evolutionary, staged progression in 
development of interventions for T2D prevention? 
I have narrowed the selection around the relevance to UK service provision, since this 
is the context for my work. 
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Figure 10: DE-PLAN map showing the centres that participated in the DE-PLAN 
programme 
5.3 Included and excluded studies 
5.3.1  Feasibility and efficacy studies 
An earlier systematic review of RCT evidence conducted by Gillies et al in 2007,6 was 
updated in NICE-R2. The Gillies review included 21 primary studies of which 17 were 
included in a meta-analysis and, of these, 9 were lifestyle interventions. Meta-analysis 
showed a pooled hazard ratio of 0·51 (95% CI 0·44 to 0·60)  and numbers needed to 
treat to prevent one case of T2D were 6.4 (95% CI 5.0 to 8.4).6   NICE-R2 included 14 
T2D prevention lifestyle intervention studies: eight that were included in the Gilles 
review, four new studies (including my submitted paper SP1); and three longer-term 
follow-ups of studies included in the Gilles review. Our BMJ evidence review included 
papers reporting lifestyle components in secondary analyses of the DPS RCT data, 
which might inform intervention development.109, 111, 112  113 
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Included studies: The first large diabetes prevention RCTs with individual 
randomisation were  the Finnish Diabetes Prevention Study (DPS)12 (published in 
2001), and the US Diabetes Prevention Programme (DPP)114, (published in 2002). The 
DPS recruited 522 overweight adults with IGT and randomised to lifestyle (diet and 
exercise) intervention or usual care control. The DPP recruited 3234 adults with IFG 
and IGT and randomised to three groups: lifestyle (diet and exercise), metformin, and 
placebo control group. Papers reporting secondary analyses of the DPS and DPP data 
have evaluated: diet, insulin sensitivity and achievement of lifestyle targets.109, 111, 115, 
116 In addition there were longer-term follow-up studies of the DPP and DPS.113, 117, 118 I 
have selected the DPS and DPP RCTs for further analysis because these two efficacy 
trials are antecedents to several translational studies as identified in NICE-R39.  
The DPS has particular relevance to my submitted papers. When the DPS was planned 
there was an intention to conduct similar, but smaller sized, intervention studies in 10 
other European centres outside Finland: the European Diabetes Prevention Study 
(EDIPS). The EDIPS centre in Maastricht, The Netherlands (SLIM study) and our centre 
in Newcastle upon Tyne, UK (EDIPS-Newcastle) completed their study arms. 
Interventions were based on the DPS protocol, although there was some flexibility for 
local variation in intervention delivery. These two studies were included in the NICE 
reviews and they have associated translational studies. The Newcastle-IGT RCT, 88, 
119which was not identified by the NICE-R2 because the primary outcome was change 
in glycaemia rather than T2D incidence, served as a methodological pilot for EDIPS-
Newcastle. 
Excluded studies: Other large T2D prevention RCT have been conducted in Japan120, 
India121, and Sweden.122 Although these contributed to answering the efficacy question 
they do not fulfil my selection criterion for analysis because they were not associated 
with translational studies. Also they are less contextually relevant to the UK. 
The NICE-R2 identified two early lifestyle intervention studies with T2D incidence as an 
outcome: the Whitehall Borderline Diabetes Study (1979),123 and the Wein study 
(1999).99  These early studies have design and sample size limitations, but provided 
evidence of feasibility that contributed to the DPS and DPP. They were not specifically 
designed as feasibility studies.   
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5.3.2  Real world effectiveness studies 
One of the review questions in NICE-R3 was about translation of RCT evidence to ‘real 
world’ situations. The review methods and study selection criteria were detailed in the 
report.9 All the translational studies identified were described as either DPP or DPS 
based (meaning the study design was influenced by the DPP or DPS protocols). Most 
used a relatively weak before-and-after study design. Of 789 papers retrieved from the 
searches 13 papers were included in the translational study section of the NICE-R3. 
Nine intervention studies (10 papers)97, 124-131 were based on the DPP protocol and 
conducted in the US, whilst three were based on the DPS protocol, two in Finland132, 133 
and one in Australia. 134  
NICE also commissioned ‘A pragmatic review of risk identification and interventions to 
prevent type 2 diabetes in high risk adults in disadvantaged and vulnerable groups’.93 
This review was restricted to UK based projects that targeted adults at high-risk of 
developing T2D with a focus on vulnerable groups. Two studies that assessed 
intermediate health outcomes were included.93 
The DE-PLAN project involved 25 centres (21 partners and four collaborators) in 17 
European countries. At the time of the final report risk assessment data collection was 
completed for 15, with a further seven expected and 21 of the centres reported 
participation in intervention activities (small pilot studies in three of these). No 
intervention outcomes were included in the report, but there have been a few 
subsequent publications from individual countries.135-137 
Included studies: I have included all three DPS based translational studies: the FIN-D2D 
study133, which was associated with the Finnish National Diabetes Prevention 
Programme;138  the GOAL study, also from Finland; and the GGT study, from Australia, 
that was adapted from the GOAL study. All these illustrate an evolutionary stage in 
intervention development that can be traced through a line of succession. The DPP 
based translational studies are less relevant to my work as there is no direct 
succession.  Two of the DPP based studies were delivered in community settings and I 
have included one of these: the Diabetes Education & Prevention with a Lifestyle 
Intervention Offered at the YMCA (DEPLOY) study as an example of a DPP based 
translation.97  Our ‘New life, New you’ (NLNY) project in Middlesbrough15 was one of 
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the two interventions identified through the NICE commissioned pragmatic review that 
assessed intermediate health outcomes.9  
Recently, the outcomes of Catalonian PREDICE study, which was part of the DE-PLAN 
programme, have been published.102 Unusually, within this DE-PLAN programme the 
PREDICE study included a control condition (non-randomised) comparator and T2D 
incidence was the primary outcome.  PREDICE was therefore an important 
translational study, providing more robust evidence than those studies with weaker 
study design and with weight loss as the primary outcome. The DE-PLAN study in 
Dresden was part of the Saxon DPP programme which is included in the 
implementation section.139  
Excluded studies: DPP based translational studies that were not delivered in 
community settings,124, 125, 127-131, 140 and one DPP based that was delivered in a 
community setting, but was quite small and delivered in a rural African-American 
church setting which was less relevant to my research question. 126 The other 
intervention, with health outcomes (apart from NLNY), identified through the NICE 
commissioned pragmatic review was ‘Khush Dil’. This study targeted South Asian 
adults living in Edinburgh.141 The PODOSA trial, which was based on the DPS, has 
subsequently been developed and Khush Dil provided evidence for PODOSA.142  
5.3.4  Implementation evaluations 
The distinction between effectiveness studies and implementation evaluation is 
sometimes unclear. In evolutionary progression an effectiveness evaluation should 
precede wider service provision and would generally be more localised and small scale. 
Service evaluation would then ideally take place once an intervention had become 
embedded.  
Included studies: The FIN-D2D133, 143 study was large scale and was conducted 
alongside the Finnish national diabetes care and prevention programme (DEKHO).144 
The Finnish national programme involved both population and high risk group 
approaches to diabetes prevention. The high-risk approach was delivered in primary 
care in five hospital districts.104 The FIN-D2D implementation has a population level 
evaluation study in which those areas where the high-risk FIN-D2D intervention was 
provided were compared with other areas of Finland.145 I believe this evaluation is 
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currently the only example of a population level follow-up to the implementation of 
T2D prevention and is important to the concept of evolutionary progression in 
demonstrating the potential for beneficial population level impact as the overarching 
outcome for public health interventions, as explained in the ‘broader focus’ expanded 
by Ogilvie et al (2009 and 2011) 
One of the DPS based translational studies, the Greater Green Triangle (GGT) study in 
Australia was subsequently expanded to a service provision programme called ‘Life!’104 
146  This implementation outwith Europe, but derived from the DPS and the GOAL 
study, exemplifies an evolutionary route that included intercontinental researcher 
collaboration. Another large scale implementation programme, the Saxony diabetes 
prevention programme (Saxon-DPP) in Germany, recruited participants using a 
modified version of FINDRISC (in common with the DE-PLAN studies), but utilised the 
DPP intervention protocol.147 148  This exemplifies an evolutionary trail that draws from 
two antecedent RCTs. Both the Saxon-DPP and Life! programmes were delivered in 
community settings and therefore provide context relevant to NLNY. 
Excluded studies:  To the best of my knowledge there are no other implementation 
evaluation studies linked to the DPP or DPS. 
5.4 Summary 
The studies that I have selected to illustrate the evolutionary stages in development 
and evaluation of interventions for T2D prevention are depicted in an evolutionary 
‘tree’ of T2D prevention (Figure 10).  I have used the visual metaphor of an 
evolutionary tree to show the evaluation stage (efficacy, effectiveness, and 
implementation) of included studies and to clarify their evolutionary lineage. In the 
next chapter I discuss my findings by drawing together my empirical work, the 
literature for primary prevention of T2D and published guidance for the development 
and evaluation of complex interventions to improve health. 
  
57 
 
  
Figure 11: Interventions for prevention of type 2 diabetes as an evolutionary tree 
Studies selected from the literature to illustrate the evolutionary progression in type 2 diabetes 
preventive interventions and provide context for my submitted papers (Key and references below). A tree 
metaphor is used here to illustrate progression from wide roots via a common lineage (efficacy) with 
divergence and proliferation to multiple adaptations in real world settings with different social and 
environmental contexts. 
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Key to Figure 10: Interventions for prevention of type 2 diabetes evolutionary ‘tree’ 
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CHAPTER SIX: PREVENTION OF TYPE 2 DIABETES IN HIGH-RISK INDIVIDUALS  
CASE STUDY ANALYSIS OF KEY FUNCTIONS AND ACTIVITIES FOR INTERVENTION 
DEVELOPMENT AND EVALUATION 
 
From my review of intervention guidance models, my empirical research and the wider 
evidence relating to T2D preventions, I have identified key functions and activities for 
development and evaluation of complex interventions to improve health. I have then 
used these key functions and activities to structure a case study analysis of T2D 
prevention and intervention guidance. This analysis is presented below with key 
functions and activities as sub-headings.  
For this analysis my hypotheses are that: 
Key functions and activities for intervention development (including those described in 
the MRC 2008 framework, others identified from the guideline review, my empirical 
research or emergent from the analysis) 20 are applicable prior to each of the 
summative evaluation stages (efficacy, effectiveness, and implementation) described 
in previous models.  
Key functions and activities will vary depending on the evaluation stage such that: 
some activities will be more appropriate at one stage than at another and how these 
activities are best conducted will vary between stages. 
Analysis of T2D prevention as a case study according to key functions and activities will 
inform the design of a new intervention guidance model. 
6.1 Evidence gathering methods 
Identifying the evidence base traditionally involves a systematic review of available 
evidence unless there is a recent, good quality review available. 20 The function and 
strength of a systematic review is in providing an unbiased assessment of existing 
evidence. Devising a systematic review search strategy is relatively straightforward for 
efficacy evidence; restriction to RCT study designs, tightly defined inclusion criteria and 
primary outcomes allow exclusive and appropriate search questions to be constructed 
that will retrieve a manageable number of studies. For efficacy evaluation in T2D 
prevention, diabetes incidence is the clinically meaningful outcome of interest. The 
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DPP and DPS were both methodologically sound RCTs with T2D incidence as the 
primary outcome, thus appropriate for efficacy evaluation and both were identified in 
the Gillies 2007 review6 and the NICE-R2.9  
However, there are some limitations of systematic reviews of efficacy evidence as 
illustrated by the case of T2D prevention and the Gillies review.6 The DPP and DPS 
have secondary analysis papers,109, 112, 115, 149 follow-up studies117, 118 113 and associated 
qualitative studies that were omitted from the Gillies systematic review. 6 In addition 
the DPS’ two sister studies (EDIPS-Newcastle [submitted paper SP1] and SLIM) are 
contributors to the RCT evidence base,11, 150 but were omitted as these were published 
later than the Gillies review and thus demonstrate the need for a review to be recent. 
Revisions, to update systematic reviews require duplication of effort and may be 
wasteful of resources or introduce inaccuracies, particularly where the evidence base 
is substantial.151 Follow-up and later studies are included in NICE-R2 and associated 
qualitative studies in NICE-R4.9   However the resources available to NICE are unlikely 
to be available to, or appropriate for, a single intervention development project.  
RCT evidence is important for efficacy evaluation, where proof of principle is the 
important function. 152 The DPP and DPS experiences illustrate the likelihood that 
respondent burdens and the long-term participant commitment would limit external 
validity, whilst the cost and capacity to deliver these interventions restricts their utility 
for real world settings.153, 154 155  
Further difficulties and limitations arise in the systematic retrieval of effectiveness 
evidence. In the case of T2D prevention this is exemplified in the search strategy for 
NICE-R3 and explained in the NICE methods guide.9, 156 In this case, and for 
effectiveness studies more generally, the evidence base may be overwhelmingly 
extensive, study inclusion criteria may be imprecise and methodology less robust 
Limitations around systematically retrieving evidence of service implementation 
include requirements for published, accessible and detailed evaluation, ideally 
including long term monitoring, that are available from situations where robust data 
collection and publishable evaluation may be a low priority. Furthermore, evidence 
utility is limited where implementation is context specific (i.e. different and specific 
health care systems). 20 
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Review methodology is imperfect. 157 In particular there are problems associated with 
synthesising qualitative evidence, 158 as well as heterogeneity issues, especially in 
relation to intervention delivery.159  
For evidence gathering there is also a need to consider local contextual evidence, such 
as might be gleaned from consultations with stakeholders (similar to ‘pre-testing’ in 
social marketing terminology)160 that may not be achieved through a systematic review 
of published evidence and that may be particularly important for real world 
effectiveness evaluations. 
As well as explaining the importance of systematic literature reviews new guidance 
should acknowledge their limitations. The balance between a review that is restricted 
by study quality (e.g. RCT evidence only) or exclusive search terms (such as pre-
diabetes) and more purposeful evidence gathering that might be better suited to 
effectiveness evaluation should be addressed. Alternative methods of evidence 
finding, such as ways to incorporate local contextual evidence should be included. 
Discussion of appropriate methodology, dependent on the evolutionary stage of 
intervention development would be helpful. 
 Systematic literature reviews have limitations 
 Evidence gathering methods other than literature reviews, such as stakeholder 
perspectives, are important 
 The relevance and importance of different evidence gathering methods vary 
according to the intervention development stage  
6.2 Behaviour change theories and participant behaviour 
Interventions to improve health at an individual level centre on enabling people to 
exert control over health determinants and thereby improve their own health, 
therefore behaviour is an important mediator. The behaviour change theory described 
in the DPS was based on the Transtheoretical Model and its Stages of Change 
construct.161 The primary behaviour change technique (or package of techniques 
related to the Transtheoretical Model) was motivational interviewing; with counselling 
sessions delivered in individually personalised consultations.162 In the DPS these 
consultations relied to some extent on the individual physical activity and dietary 
monitoring assessments (i.e. coding, analysis and feedback of individual food and 
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physical activity diaries). This detailed individual assessment and feedback is time-
consuming, carries respondent burden (which may restrict inclusion by socio-economic 
status and affect external validity), is impractical for group delivery and not scalable for 
implementation. Thus, the DPS protocol clearly requires much modification for the 
intervention to be practical in a real world setting. As a case study this exemplifies the 
need for reworking of an intervention methodology that was appropriate for efficacy 
evaluation. Reworking intervention methodology means that key developmental 
activities, including assessment of feasibility and acceptability, need to be revisited 
prior to effectiveness evaluation.  
In the GOAL effectiveness study, there was a strong focus on behaviour change 
theories including the Health Action Process Approach (HAPA). 163, 164 The aim to 
determine and describe the behaviour change processes 165 is a strength of the GOAL 
study and this detailed description facilitated the development of the Greater Green 
Triangle (GGT) study based in Victoria, Australia, which utilised similar behaviour 
change process methods.134 Detailed descriptions of the behaviour change processes  
are important for intervention replication.166 However, over-burdening participants 
with data-collection instruments could restrict participation and affect retention, 
particularly where there are cognitive or language difficulties. A need for balance 
(between comprehensive data collection and respondent burden) is applicable to 
guidance generally and especially relevant in developing equitable interventions for 
effectiveness evaluations. 
 The  most appropriate balance between comprehensive process data collection 
and respondent burden varies depending on the intervention development 
stage  
6.3 Behaviour change theories and staff behaviour and motivation  
Interestingly the GOAL translational study acknowledged the importance of facilitator 
motivation to promote intervention success. Often a pioneer research team, that is 
responsible for intervention development, might be highly motivated, but this cannot 
be assumed for all delivery centres as an intervention is rolled-out. In expanding an 
intervention beyond the early pioneer team,167 facilitator motivation and ways in 
which this might  be maintained, such as including a degree of facilitator autonomy, 
should be considered for good intervention design.168 In contrast to the GOAL study 
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approach, the DEPLOY study protocol relied on a 16 week set of structured lesson 
plans extracted from the DPP curriculum.169 This highly structured model is useful in 
ensuring consistency of application, but loses flexibility of approach.168 Where the 
delivery relies on specially trained lay health coaches, a tightly structured paradigm has 
merit in providing a reliable, replicable model. The effect of this prescriptive approach 
on facilitator motivation and participant retention in the longer term is uncertain. 
There is tension between the needs for: adherence in intervention delivery; flexibility 
for context appropriate adaptations; and autonomy to promote provider ownership. 
An appreciation of this tension and options for its resolution could be expanded in 
devising new evaluation guidance. 
 Motivation of Intervention delivery staff is important and may be affected by 
their degree of autonomy Tension between protocol adherence, facilitator 
motivation and context may affect intervention delivery  
6.4 Design drift and protocol comparison 
The intervention design drift, between individual delivery and the theory underpinning 
the DPS and DPP, to programmes where interventions are delivered at group level 
represents a major difference in protocol.161 This may be necessary from a cost and 
capacity perspective, but the assumption of equivalent efficacy is unwarranted. Any 
added benefit in incorporating elements of social interaction, 170, 171 or evaluation of 
reach and inclusivity are untested. The DEPLOY intervention is described as ‘Based on 
the DPP curriculum,’ but it is not clear which components are retained in full and 
which have been modified. There is no DPP ‘brand standard’ to be achieved in order to 
describe an intervention as ‘DPP based.’  In a commercial situation branding clarifies 
the model and provides some guarantee of quality. The issues of intervention brand or 
other mechanisms to identify quality and fidelity are important for implementation, 
and could inform intervention guidance. 
We do not know whether the intervention delivery or the behaviour change strategies 
used in either the DPP or DPS were optimal, only that these different intervention 
paradigms were similarly effective. Both the DPP and DPS included group led physical 
activity sessions. This intervention feature is seldom preserved in real world settings. 
Between study comparisons of different intervention protocols to draw out common 
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components in interventions of proven efficacy, is an evaluation function that could 
usefully be included in new intervention guidance. 
 Protocol comparisons, across studies with similar research aims, could provide 
useful evidence 
6.5 Incorporating concurrent advancement in related fields and 
technologies 
Application of behaviour change strategies more broadly also evolved during the 
evolution of T2D prevention. Whereas when the DPS was planned specifying a 
behaviour change theory was best practice, we might now anticipate a more explicit 
pragmatic focus on behaviour change techniques.172 One advantage of using behaviour 
change techniques is the opportunity to evaluate their use in intervention delivery as 
an outcome of interest.173 Assessment of the behaviour change techniques used in 
delivering an intervention could provide a fidelity measure that does not rely on 
prescriptive session plans. Reviewing the concurrent evolution in understanding and 
application of behaviour change theory (alongside intervention development) is a 
more generally applicable activity for inclusion in intervention guidance. 
As technology advances, new opportunities for intervention design and data collection 
such as accelerometer measures of physical activity174 and electronic communication 
with participants become available. The opportunity to incorporate concurrent 
advancement of technology alongside intervention evolution would also be usefully 
addressed in a new guidance model. 
 As interventions evolve through staged progression other technologies also 
evolve and provide new opportunities for intervention development  
6.6 Modelling intermediate health outcomes 
In the case of T2D prevention, the DPS and DPP participants were overweight or obese 
(defined by inclusion criteria, with different criteria by ethnicity within the DPP).175 For 
modelling purposes the lifestyle targets, (weight loss (5% [DPS] or 7% [DPP]), dietary 
changes and increased physical activity) advocated in the DPS and DPP were clearly 
described.169 In secondary analysis, lifestyle changes were modelled to the primary 
outcome (T2D incidence).109, 110, 115   
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As a candidate for modelling, weight loss can be easily and objectively measured, and a 
weight loss target is an assessable intermediate health outcome. Although physical 
activity can also be objectively measured, this was not done in either the DPS or DPP, 
probably due to the limited technology available at the time. Physical activity was 
assessed in these trials with self-report, diary-style instruments. Although a similar 
self-report measure, or an objective measure of physical activity, is a possible 
intermediate proxy for T2D incidence (behavioural outcome), it might be more 
convincing if supported by weight loss measurement.109 On the other hand, 
measurement of dietary components is difficult.  Available objective dietary measures 
include plasma vitamin C and carotenoids that may be useful for modelling .91 The 
dietary targets in the DPS and DPP were expressed in ways that can only be accurately 
determined by coding and analysing individual food diaries. Dietary changes are not 
useful as modelling criteria.  
An advantage of using intermediate health outcomes (e.g. weight loss rather than T2D 
incidence) is to facilitate evaluation within a shorter timescale. However the timescale 
for behaviour change to be embedded remains a consideration and maintenance of 
weight loss or physical activity increase cannot be assessed in short studies. The 
National Obesity Observatory (NOO) Standard Evaluation Framework suggests that 
where weight loss or physical activity increase are the outcomes of interest these 
should be assessed in interventions of more than one year’s duration.176 The GOAL 
study reported weight loss at 1 and 3 years of follow-up.132, 177 Although the mean 
weight loss was less than reported in the DPS, the fact that this loss was maintained at 
three years suggests possible intervention effectiveness. The GOAL study, in common 
with most ‘real world studies’ was limited by lack of a randomised control group.  
Although weight loss can be modelled to T2D incidence using DPP,90 DPS,12 or EDIPS13 
data this only equates to a population identified by IGT. We should not assume that 
weight loss would demonstrate the same preventative effect in a differently identified 
population.13  
In a new guidance model the limitations associated with extrapolation of intermediate 
health outcome data for modelling purposes, such as where an intervention is applied 
to a differently identified population or where intervention protocols have ‘drifted’ 
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some way from the original efficacy study designs, should be acknowledged with an 
explanation that assumption of similar primary outcome effect is insecure.  
 Modelling of behavioural and intermediate health outcomes may be used to 
reduce an evaluation timescale  
 However, the limitations of modelling, relative to empirical research, should be 
acknowledged 
6.7 Testing procedures: feasibility, acceptability and stakeholder 
perspectives 
Procedures for the DPS and DPP were prescribed in detailed research protocols and 
were intended to provide best conditions for success with limited consideration of cost 
or large scale capacity to deliver.178 In the T2D effectiveness and implementation 
studies analysed here, the lifestyle goals were similar to the original RCTs, but 
recruitment strategies, delivery mode, delivery staff, intervention content (in some 
cases)and primary outcome measures were all different.  
In the FIN-D2D study145 intervention procedures for high-risk individuals were based 
on the DPS intervention, with local, resource dependent variations.133 The retention 
rate of 50% of the total cohort at one year reflects the difficulties in participant follow-
up in real world settings. 
The GGT study134 used social marketing techniques and pre-testing with 
stakeholders160 to develop a DPS based intervention. A similar feasibility procedure is 
advocated in the MRC 2008 framework (MRC case study 3 Rudlof et al 2006)179 
The implementation of the Saxon-DPP has precisely defined management and 
administration structures and is delivered in community settings by ‘prevention 
managers’ who work independently and are employed by the TUMAINI institute.147 
The institute is responsible for the programme content (including provision of 
standardised materials), administration and quality assurance. Prevention managers 
receive a basic salary (30%) and performance related pay (70%). Efficient 
administration procedures are vital for research conduct and follow-up at any stage, 
but the scale of administration for implementation makes this an important issue that 
may not be evaluated or reported in academic literature. In addition inclusion of 
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performance related pay introduces a commercial approach to intervention delivery. 
Commercial intervention strategies could be further researched. 180, 181 
 Administration procedures are important, especially for large scale 
implementations, and often poorly reported 
 Stakeholder perceptions are important in evaluating feasibility and 
acceptability 
6.8 Determining inclusion criteria for sample size estimation 
The DPS and DPP recruited adults with persistent IGT (IGT on two consecutive OGTT 
tests). This strategy defined a coherent high-risk population group using an objective, 
exact parameter that was appropriate for an efficacy trial, and allowed sample size 
calculation. The DPP recruitment strategy included identifying committed participants 
who were able to cope with data burden in order to ensure complete data collection 
as far as possible.178  
The predictive sensitivity of IGT for progression to T2D within 7.5 years, in the San 
Antonio Heart study was  50.9% (a mean rate of 6.8% per year) 182and in other studies 
rates between 4% and 8% per year, depending on the population, were reported. 183 
The sample size for the DPS RCT was based on an estimated between arm difference of 
35% in five years.65 As repeat OGTT testing is time consuming, inefficient and 
burdensome (both in terms of cost and participant inconvenience), the OGTT is not 
considered appropriate for risk identification in real world situations.9 Alternative ways 
of identifying high-risk individuals for real world intervention provision are needed.  
The Finnish prospective risk score ‘FINDRISC’ can be used to identify different levels of 
risk for future T2D expressed as percentage 10 year risk.72 The concise FINDRISC 
comprises: age, gender, BMI, waist circumference, hypertension (as drug treated 
hypertension), family history of T2D and knowledge of previous hyperglycaemia. It is 
usually completed as a self-report calculator. The standard version of FINDRISC also 
includes a question about physical activity and one about berries, fruit and vegetables. 
These last two questions are principally included to introduce lifestyle considerations 
for discussion rather than for their ability to add to the model’s predictive power.  
The FIN-D2D, translational study within the high-risk T2D prevention implementation 
strategy recruited on either of four high-risk measures (FINDRISC score ≥15, previous 
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gestational diabetes, previous ischemic event, or known IFG or IGT) and those at high-
risk were referred for an OGTT to exclude prevalent T2D.184 The GTT study recruited on 
the basis of the Australian AUSDRISK (which was derived from FINDRISC) risk-score tool 
(score >12) with blood glucose measures (IFG or IGT) to exclude T2D104, whilst the 
GOAL study recruitment strategy was based on FINDRISC score ≥ 12.185  A risk score 
recruitment strategy was similarly used in the DE-PLAN suite of studies, including the 
PREDICE study (FINDRISC ≥ 14 or FINDRISC < 14 with IFG or IGT).186 136 The American 
community based DEPLOY study recruited on the basis of BMI >24 kg/m 2, ≥ 2 diabetes 
risk factors and capillary HbA1c 110 to 199 mg/dL. 97  
The Saxony-DPP, and the PREDIAS block randomised controlled trial within the 
Saxony–DPP, used a prospective risk score (German-FINDRISK score >10) or risk 
assessment according to a primary care physician followed by capillary HbA1c testing 
to exclude prevalent T2D.187 Mixed inclusion criteria make sample size determination 
for controlled intervention with T2D incidence as a primary outcome very difficult. 
An optimal and pragmatic strategy to identify high-risk individuals for the purpose of 
intervention where reduction in T2D incidence is the primary outcome has not been 
determined.13 This evidence gap is included in the research recommendations of the 
NICE guidance.9  
 Robust research study design, clear inclusion criteria and accurate sample size 
calculation is crucial at any stage to produce robust evidence of effectiveness 
and cost effectiveness 
6.9 Assessing reach and equality 
For efficacy and other controlled studies accurate estimation of sample size is 
important. However, reach, external validity, and equality issues may be considered 
less important for efficacy trials than for effectiveness studies (and are arguably 
unachievable). Guidance for evaluation of reach is described in the conceptual 
intervention guidance models MOST, which is explained as a multiphase optimisation 
strategy that includes screening, optimisation with factorial analysis to identify active 
components and refining, 188 189and RE-AIM (Reach, Efficacy/Effectiveness, Adoption, 
Implementation, and Maintenance).32  A new guidance model should expand on the 
relevance of different outcome variables to the evaluation stage. 
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 The value of an intervention is not only about the effect size, as outcome 
difference between intervention and control groups, but has other dimensions 
including equity. 
 The relative importance of different evaluation dimensions will vary according 
to evolutionary intervention stage. 
6.10 Choosing evaluation study design 
Randomisation is the procedure that best avoids bias between intervention and 
control groups for evaluation. The primary outcome of interest in the DPP and DPS 
RCTs was T2D incidence, which is a clinically meaningful outcome, providing strong 
evidence of differential effect.6 The T2D risk reductions reported in the DPS, DPP, and 
other similar RCTs were remarkably consistent and meta-analyses have provided 
review level evidence of efficacy.6, 9 These RCTs have strong internal validity, but 
external validity is questionable as respondent burden and long term commitment led 
to self-selection.148 The DPP had percentage targets for females (exceeded) and ethnic 
minority groups (under recruited), and failure to recruit to target is a limitation of this 
study.148 
Weak study design, reliance on intermediate outcomes and imprecise inclusion criteria    
limit T2D effectiveness assessments. Modelling of weight loss to T2D incidence cannot 
be assumed for differently identified populations. Only the recently published PREDICE 
real-world effectiveness study had T2D incidence as a primary outcome measure.102 
The large scale implementation programmes, Saxon-DPP in Germany and Victoria State 
Life! Programme in Australia,104 built on these limited effectiveness studies with similar 
design and recruitment procedures. 190 In the Saxony-DPP the incorporation of the 
nested RCT could have been better used to assess the external validity if there had 
been a recruitment audit trail to determine the representative nature of the within 
service recruitment. 32 
A logical structure for deciding which evaluation designs might be most appropriate for 
different evolutionary stages would be a useful addition to a new guidance model. 
 Individual randomisation is robust for demonstrating intervention effect, but 
external validity may be limited 
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 The most appropriate evaluation study design might vary by evolutionary 
stages of intervention development 
6.11 Analysing change process 
The shift of emphasis, from what will provide the best chance of intervention success 
(efficacy) to scalability (implementation) underlines the importance of properly 
analysing the change process and determining the essential active ingredients of the 
‘successful’ intervention. There is a danger that burdensome procedures might 
promote intervention generated inequalities.191  
Qualitative or other in depth evaluation of the behaviour change processes within T2D 
prevention trials, could have been used to modify and improve the strategies, but the 
scarcity of this information 9  limits the utility of the trials to inform intervention 
evolution. The NICE-R4 9 review that addressed views, barriers and facilitators relating 
to T2D prevention in adults with IGT or IFG included a total of 14 published studies, of 
which only seven related to barriers and facilitators to changing lifestyle behaviours 
(four qualitative and three survey based).18, 192-197 One qualitative study was nested 
within the DPS195, one within EDIPS-Newcastle18, and the other within the GOAL 
study.194 This lack of process evaluation in the T2D prevention trials is a missed 
opportunity. 
Understanding participant perspectives is important for developing the next 
intervention stage, and it would now be considered good practice to include trial 
related qualitative work as formative process evaluation.198  
 Qualitative evaluation may inform intervention refinement between 
evolutionary phases without adverse impact on general respondent burden 
6.12 Assessing cost effectiveness 
To assess cost effectiveness a comparative unit used in health economics is the Quality 
Adjusted Life Year (QALY). 199 There are other comparative units (e.g. Disability 
Adjusted Life Year DALY), but the QALY is the NICE standard.200 QALY assessment 
includes both cost and benefit that allows comparison of different treatments for one 
condition and a specific treatment for different conditions.  
The utility of the QALY should be to facilitate comparison of treatments for allocation 
of resources, for example within the UK NHS, aiming at efficient use of limited 
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resources. Preventive interventions are problematic for resource allocation as 
prevention requires money to be spent ‘up front’ for health gains in the longer term. 
Therefore it is difficult for spending on prevention to compete equally with spending 
on treatments for prevalent ill health, particularly where decisions are made at a local 
level. In addition in the UK the recent allocation of health promotion to local 
government means that there are now different budgets for preventive interventions 
and treatment of ill health. Thus any financial benefit due to Local Government 
investment in preventive intervention would be reaped by the NHS. Long term 
prevention initiatives may require more strategic policy level funding allocations such 
as ‘ring fenced’ monies.201 
To make a resource allocation case for preventive interventions, evidence based 
comparison of cost and benefit of pragmatic ‘real world’ preventive interventions is 
vital. This might include modelling of efficacy evaluations, including estimation of 
longer term consequences.202 There are cost-benefit and cost-effectiveness 
assessments based on the DPP and DPS, although variation in the exact inclusions (e.g. 
does it include screening costs?) and modelling duration for outcome events in 
different published scenarios can make it difficult to extract the meaning and 
relevance to inform intervention planning.9 There are also problems of costings in 
different countries and health care systems that compound the extraction of 
meaningful information. For meaningful analysis, the screening costs and progression 
rates related to baseline risk need to be included as well as adjustment for the cost 
and benefit of early detection and treatment of T2D (as a result of screening for risk 
factors). 9  
Health economic evaluation was conducted in association with the recent NICE 
reviews.9, 80 However, the economic modelling for intervention in high-risk individuals 
was based on evidence extrapolation which included putative estimates of 
intervention benefit in a population with different baseline risk assessment criteria 
and with different intervention delivery.  
In the case of diabetes prevention in high-risk individuals, where there is a clinically 
meaningful outcome that can be proven within a reasonable timescale, a robust health 
economic case for resource allocation should be possible and persuasive, but it needs 
a proven and practical (implementable) evidence base.   
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 Prevention requires monies to be spent ‘up-front’ for long term health gains. 
6.13 Robust assessment of ‘real world’ studies is vital to inform resource 
allocation. Assessing cost and capacity to deliver 
To provide funders with the information required to allocate investment in a 
preventive intervention a useful presentation of budget options would be as a 
business case. There is a disconnection between the economic modelling, where the 
output is presented as cost per QALY and the information that service commissioners 
and providers need. NICE has provided costing tools to help address this gap. 
However, even when the intervention cost per QALY clearly demonstrates cost 
effectiveness, implementation still depends on available resources and on decisions to 
allocate resources to prevention, against the demands of other services, especially 
demands of acute health care provision. As highlighted above, in the UK, there is also 
a disconnect between investment by local government for the NHS to reap rewards in 
terms of reduced health care costs. 
 Prevention resources may need to be specifically allocated ‘ring fenced’. 
6.14 Reporting 
Reporting is important across all stages of intervention development. Publication in 
the research literature is essential and should be included in intervention guidance.20  
Reporting  of the DPS and DPP primary outcome and secondary analyses has been 
extensive and frequently cited.203 T2D prevention studies have also been widely 
disseminated through conferences and various events including World Conferences for 
the Prevention of Diabetes and its complications (WCPDs).  
However, publication of effectiveness studies may not be comprehensive, especially 
where these studies are small scale or ineffective.  Publication bias favours RCT and 
‘new’ research evidence. 204  Successful translation of efficacy research to the real-
world is problematic and where these efforts fail, publication may be particularly 
difficult to achieve. Even when effectiveness research is published it may be excluded 
from a systematic review where searches are restricted by study design or key-words. 
For example the DE-PLAN project map (Figure 9) identifies numerous intervention 
centres many of which do not appear to have associated publications. The 2010 WCPD 
organisers invited contributions for a book, ‘Diabetes Prevention in Practice.’104  
Contributors to this book were subsequently invited to revise their chapters for a 
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special edition of the British Journal of Diabetes and Vascular Disease.15 There is an 
opportunity for high impact journals to support effectiveness research by publishing 
special editions in this way. There may also be an opportunity for large research 
funders to influence and reduce publication bias. 
 Reporting is important at all intervention stages 
 Journals and funders have potential to support effectiveness research through 
promoting publication 
6.15 Dissemination (Roll -out) 
When small scale interventions are rolled-out to larger service provision there is a 
danger that limited resources205 may lead to a weakening of intervention quality. This 
was highlighted in reflections from the Victoria state, ‘Life!’ team.206 They have 
identified important components of the GGT study (Individual session prior to joining 
the group, individual feedback on diet and physical activity diaries, feedback to 
participant on their blood pressure and cholesterol results at 3 and 12 months, funding 
for recruitment costs) that are missing from the service model. The ‘Life’ team have 
also detailed ‘other wisdom gained’, from their experience of expansion from the GGT 
roll-out study to wider service provision, among which is the advice to expand through 
a pilot and incremental roll-out and the need for social marketing (advertising) 
campaigns (run in parallel to the high-risk approach) to raise awareness of the 
seriousness of diabetes, risk assessment and prevention potential. 206 
 Incremental intervention roll-out may improve fidelity 
 Individual and population level interventions may benefit from  parallel 
dissemination 
6.16 Links between programmes 
The national programme in Finland included a population awareness raising strategy 
alongside a high-risk intervention strategy. The large-scale implementation 
programmes for diabetes prevention in Finland and Saxony have been instigated as 
top-down approaches, including both population (raising awareness) and high-risk 
(intervention targeting individuals) strategies. In Finland, the high-risk intervention was 
incorporated into existing primary care structures, whereas in Saxony the intervention 
provision was organised through the TUMAINI institute. High-level organisation and 
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funding commitment is required to accomplish such large-scale strategic 
approaches.206  
 Co-ordinated approaches to large scale intervention dissemination require 
high-level policy commitment 
6.17 Fidelity of intervention delivery and staff training 
The GOAL study, as detailed previously, highlighted the importance of practitioner 
motivation in intervention delivery.134 Successful implementation is not just about 
large scale plans and funding, but also about capacity, and facilitator training and 
commitment. Both the Life! And the Saxony projects had large associated facilitator 
training plans. 134, 207 The Life! authors point out the difficulty of coordinating 
participant recruitment rates with the availability of appropriately and recently trained 
intervention delivery staff. Variations in training quality could impact intervention 
fidelity and effectiveness 
 Co-ordinated training of intervention delivery staff is vital for successful 
intervention implementation.  
6.18 Surveillance and monitoring 
For surveillance and monitoring of service provision to be possible in the long term, 
data-collection systems need to be incorporated within the programme delivery, not 
just as research add-ons. This is really a design issue that echoes the need for 
collaborative intervention development that involves both research and service 
providers.  The Saxony programme has ‘quality measures’ that are evaluation outcome 
measures, based on individual participant data, including participant waist and blood-
pressure measurement, as prescribed requirements for the programme managers to 
return via an online database. There is thus an emphasis on intermediate health 
outcomes, rather than softer measures such as ‘knowledge gained’ or ‘intention to 
change’ or ‘fidelity of programme delivery.’ There is indication of payment by 
outcomes achieved as a surveillance measure in this programme. However, payment 
(of managers) by outcomes, where outcome data is returned by the same managers 
would require careful auditing. 
The recent publication relating to the implementation of the FIN-D2D high-risk 
intervention plan, 145 alongside Finland’s national diabetes programme is important in 
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demonstrating the additive effect of multiple intervention strategies. The need for 
awareness raising initiatives alongside high-risk intervention provision was also 
identified in the Life! programme.134, 208 
 Long-term monitoring procedures should be built into intervention 
effectiveness design  
 Collaboration between research and service partners is needed to facilitate 
incorporation of monitoring in intervention design. 
6.19 Long term follow-up 
Long-term follow-up could be applied at any evaluation stage Both the DPP and DPS 
have reported long term follow-up evaluations.117, 118 113The DPS started recruitment in 
1993. Different centres began recruiting at different time points and the recruitment 
was protracted. In March 2000, the independent end point committee recommended 
that the trial be ended. Following the completion of the active trial, participants 
continued to be followed-up with assessments, annually at first and bi-annually later. 
As a result there is considerable and valuable long term follow-up data from this study. 
Similarly the DPP has reported follow-up results at 10 years after the end of the active 
trial phase.  
 Long-term follow-up is important at all evaluation stages 
6.20 Summary 
Review of intervention studies, which span the biomedical research continuum, for 
T2D prevention in high-risk individuals with reference to key activities and functions 
for intervention development, supports the utility of a staged evolutionary construct in 
intervention development and evaluation. This analysis suggests that differentiation of 
intervention development and evaluation strands, with defined decision points would 
clarify guidance and improve its utility. Summative evaluation points, efficacy, 
effectiveness, implementation and sustainability are appropriate to provide evidence 
to support decisions regarding the next stage and should be complemented by process 
evaluation and evidence synthesis. 
This analysis of T2D prevention studies clarifies the need to repeat key functions and 
activities of intervention development prior to each summative evaluation point and 
supports the concept of variation in these key functions and activities that are 
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dependent on the evolutionary stage of intervention development. A model based on 
evolving design and redesign loops would improve clarity and also facilitate the 
incorporation of advances in related fields and technologies alongside evolutionary 
progression of intervention development. As intervention development progresses to 
service provision the tensions between fidelity and flexibility, reach and equity, 
sufficient data and respondent burden, as well as cultural acceptability, contextual 
adaptations, and stakeholder perspectives become increasingly important.  
The analysis of T2D prevention outlined in this chapter is informed by my research 
experience in the field. This empirical research, which is presented in my submitted 
papers, provides the fundamental underpinning to the analysis.  In the next chapter I 
reflect on this research and my experience of T2D preventive interventions, conducted 
at Newcastle University. I have written this as a reflection to explain the way my 
thinking has evolved and to clarify the pivotal role of this empirical research to my 
thesis.  
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CHAPTER SEVEN:  PROPOSED NEW GUIDANCE FOR THE DEVELOPMENT AND 
EVALUATION OF COMPLEX INTERVENTIONS TO IMPROVE HEALTH 
 
7.1 Information to support new guidance  
The guidance review, analysis of T2D prevention case studies and reflection on my 
empirical T2D prevention research support a need for revised guidance. 
I have identified the benefit of separate intervention development and evaluation 
strands with progressive summative evaluation points. Separating intervention and 
evaluation strands facilitates optimisation of each strand.30 Key activities of 
intervention development and evaluation include: 
 Evidence gathering methods 
 Behaviour change theories and participant behaviour 
 Behaviour change theories and staff behaviour and motivation 
 Intervention design drift and protocol comparison 
 Incorporating concurrent advancements in related fields and technologies 
 Modelling intermediate health outcomes 
 Testing procedures: feasibility, acceptability and stakeholder perspectives 
 Determining inclusion criteria for sample size calculations 
 Assessing reach, recruitment, retention and equity 
 Choosing evaluation study design 
 Analysing change processes 
 Assessing cost effectiveness 
 Assessing cost and capacity to deliver 
 Reporting 
 Dissemination (roll-out) 
 Links between programmes 
 Fidelity of intervention delivery (adherence and competence) 
 Training procedures (staff training, health champions, peer support) 
 Surveillance and monitoring 
 Long-term follow-up 
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An intervention design loop with selected activities could be employed with great 
benefit at each evolutionary stage, supported by formative process evaluation, to 
promote stage-related optimisation of intervention and evaluation strands. Redesign 
at progressive stages will also facilitate design updates to reflect progress in related 
methodology and technology.  
Following intervention optimisation, a pause in the development process, such that a 
defined intervention is delivered as intended (per-protocol) with adequate fidelity and 
minimal modification, will facilitate summative testing at the efficacy and effectiveness 
evaluation stages.  Quantitative summative evaluation is needed to test pre-defined 
and measurable outcomes of interest. Definitive evaluations require experimental 
study designs. Variations in the outcomes of value between efficacy and effectiveness 
evaluation will influence the choice of study design. Beneficial outcomes that were not 
anticipated may be evidenced from qualitative summative evaluation. 
Analysis of the T2D prevention case studies suggests that effectiveness evaluation may 
require more than one iteration to separately evaluate important intervention 
adaptations. In my proposed new guidance model I have distinguished two steps in 
effectiveness evaluation. The first step is to evaluate intervention effectiveness on a 
limited scale, where the inclusion criteria are more narrowly targeted than might be 
equitable for service provision.  The second step is to evaluate adaptations of the 
intervention model, that might be necessary to ensure equitable service provision 
(such as for different ethnic groups or for different age ranges) or that might have 
further potential (such as extending the intervention model to related conditions). 
Following implementation of an intervention as service provision, on-going monitoring 
is necessary to assess intervention performance and the degree to which the 
intervention continues to be delivered as evaluated. At this stage a pause in 
intervention development is not feasible. A degree of design drift is inevitable, such 
that context variations in intervention provision will evolve, and thus it is important to 
incorporate training and monitoring procedures in the intervention design that will be 
retained after the formal research evaluation of effectiveness has been completed.  
Monitoring, evaluating sustainability and equity are important aspects of intervention 
development and design for sustainable service provision. These aspects are not well 
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served by current guidance. It may be necessary to develop new experimental 
methods to address the issue of maintenance of intervention effectiveness.  
Progress decisions should be made following each evaluation stage depending on the 
outcomes: such as demonstration of effect; fitness of the intervention for progression 
to the next evolutionary stage; and options for modification/optimisation, adaptation, 
updating, and improvement.  
7.2 A proposed new guidance framework: the evolutionary decision tree 
Having identified a need for revised intervention guidance and determined the 
necessary constituents and their organisation, which I suggest are required for refined 
guidance, I propose a new framework diagram. This framework diagram is designed to 
present clearly the organisation of key activities and functions of guidance for the 
development and evaluation of complex interventions to improve health. It is my 
intention that this framework diagram will be easy to assimilate, memorise and recall. 
To facilitate ease of recall I have used the concept of repeated developmental units or 
‘building blocks’ overlaid on the metaphor of an evolutionary decision tree. I have 
incorporated standard flow-chart and decision tree formats with hierarchical 
relationships, intra-hierarchical cycles, decision nodes and feedback loops. Familiarity 
of formatting is included to draw on meaningful associations to promote effective 
communication and assimilation. The building blocks have structural similarities at 
each evolutionary stage, although the most relevant key activities (as above) will vary, 
depending on the evolutionary stage.  Building blocks for efficacy and effectiveness 
stages (Figure 12) are structured to design, test and decide as explained below:  
 Design: a design loop that has intervention development and formative 
(process) evaluation strands; followed by 
 Test: a pause in intervention development for the purpose of summative 
evaluation, which may include both quantitative and qualitative methods; 
followed by 
 Decide: a decision node where the choices are informed by the outcomes of 
the preceding summative evaluation and are to: proceed to the next 
evolutionary stage;  feedback to refine the intervention before proceeding; or 
decide not to progress further 
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The building block for the implementation stage is differently structured to reflect the 
probability that a pause in intervention development, to allow summative evaluation, 
is not appropriate at this stage (Figure 13). Thus summative evaluation is replaced by 
monitoring procedures that run concurrently alongside a minimal intervention 
development strand. Implementation should be focussed on delivering an intervention 
of proven effectiveness with fidelity. Fidelity is about adherence to the intervention 
protocol and competence to deliver an intervention in a specific context. It is 
acceptable for an implemented intervention to incorporate minor variations to update 
and refresh the original design. However any radical intervention change that 
compromises its fidelity needs to be subjected to re-evaluation of effectiveness. In the 
UK, services are usually commissioned with a cycle of three or more years. If effective 
monitoring procedures are in place they will contribute to a decision to retain a service 
or to decommission at the end of a commissioning cycle. Thus a decision node is still 
relevant for implementation design. The implementation building block (Figure 13) is 
structured to deliver, monitor and decide.  
When put together the building blocks form an intervention development and 
evaluation evolutionary decision tree that shows progressive stages. The basic stages 
are:  
 Efficacy: intervention development and design and optimisation with process 
evaluation, culminating in a pause for efficacy evaluation 
 Effectiveness: intervention redesign and optimisation with process evaluation 
resulting in a  pragmatic and implementable intervention for specific ‘real 
world’ settings, culminating in an intervention development pause for 
effectiveness evaluation  
 Effectiveness (replication and adaptation): context specific intervention 
redesign and optimisation for broader settings) culminating in an intervention 
development pause for effectiveness evaluation, which may be linked across 
intervention areas/populations 
 Implementation: intervention implementation, with monitoring and innovation 
feedback, on-going evaluation of service provision. 
81 
 
Figure 12: ‘Design-Test-Decide’: repeated unit building block of a proposed new 
guidance framework for the development and evaluation of complex interventions 
to improve health (efficacy and effectiveness stages) 
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Figure 13: ‘Deliver/Monitor-Decide’ repeated unit building block of a proposednew 
guidance framework for the development and evaluation of complex interventions 
to improve health (implementation stage) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key to figure 13 Key activities and functions applicable to different 
summative evaluation stages 
 
Intervention delivery: updating  evidence and theory, 
incorporating flexibility to context and minor innovations 
and adaptations, training and administration, linkage to 
policy and practice 
 
Monitoring: fidelity of intervention delivery: adherence 
and competence, relevance and acceptability to 
stakeholders 
 
Evaluation of sustainability: comparison with earlier 
recruitment and effectiveness outcomes, suitability to 
retain as a commissioned service 
 
Decision node: maintain commissioned service, feedback 
to refine the intervention and retest, monitoring outcomes 
do not support continuation 
 
Pathways: routes available to take from the decision node 
with arrows to show the direction (feedback, feed forward) 
 
Pathways: routes available to take from the decision node 
(do not proceed) 
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An evolutionary decision tree diagram incorporating the different stages composed of 
the unit building blocks is shown in Figure 14. This diagram contains some linking 
elements in addition to the unit building blocks. The solid green line on the left 
represents the underlying basic science and epidemiological evidence base, from 
which the initial problem identification and solution generation emerge. This baseline 
will also be influenced by policy and existing practice. The solid blue line at the 
conclusion of the effectiveness evaluation stage represents the linkage between 
effectiveness evaluation in different locations that feeds back to contribute to the 
general underlying evidence from which new initiatives may emerge.  The dashed 
green lines represent the fact that, even when interventions do not progress, the 
information generated by conducting robust evaluation will feed back to the 
underlying evidence base and play a part in increasing knowledge that may eventually 
lead to a different approach. 
The staged progression intervention guidance blocks, familiar to those who have used 
early guidance models such as the Nutbeam model and the MRC 2000 framework, are 
overlaid (grey boxes) onto the tree diagram. The iterative nature of development and 
evaluation of complex interventions to improve health is divided into within-stage 
‘Design-Test-Decide’ loops (or ‘Deliver/Monitor-Decide’ loop for the implementation 
stage) and an overall feedback system, such that each stage adds to the evidence base.  
7.3 Summary 
Analysis of intervention guidance using T2D prevention as a case study supported a 
revised guidance model, which I have outlined in a framework diagram (Figure 14 
below). 
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Figure 14: Evolutionary decision tree diagram showing the stages in the development 
and evaluation of complex interventions to improve health 
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CHAPTER EIGHT: DISCUSSION 
8.1 Principal findings 
8.1.2 Type 2 diabetes prevention: my empirical work 
Research evidence from RCTs demonstrated the efficacy of lifestyle intervention for 
T2D prevention. The EDIPS Newcastle trial arm contributed to this evidence and the 
study results suggested that similar intervention effect could be achieved in the UK. 
Secondary analysis of collated EDIPS data underlined the importance of weight loss 
maintenance in the reduction of T2D incidence and highlighted issues regarding 
efficient risk identification for pragmatic effectiveness evaluation and large scale 
intervention provision.  
Development and evaluation of the NLNY pilot study to date, in a local area of social 
deprivation, suggests that this intervention model is feasible and acceptable, is likely to 
be effective in promoting weight loss at one year, and is scalable for targeted service 
provision. As the NLNY intervention is based on the lifestyle change targets described 
in the EDIPS protocol, it is also likely to be effective in reducing T2D incidence in high-
risk individuals. In the EDIPS Newcastle trial arm weight loss at 12 months was an 
important intermediate health outcome and predictor of reduced five year diabetes 
incidence in this population. However, the EDIPS Newcastle trial population comprised 
adults with IGT identified through repeated OGTT measurement. This risk 
identification procedure is not considered suitable for service provision in the UK.9  A 
definitive trial evaluation of the NLNY intervention, with diabetes prevention as the 
primary outcome of interest is needed to demonstrate effectiveness and assess 
efficiency. In piloting NLNY we identified the need for intervention adaptations to 
promote engagement of ethnic minority communities in order to achieve equitable 
intervention provision. Adaptations of the NLNY intervention for ethnic minority 
communities need further development prior to formal evaluation. 
8.1.2 Analysis of intervention guidance  
In this review of intervention guidance I identified bio-medical, sociological and more 
purpose focussed approaches to guideline development. Also I identified strengths and 
limitations of existing frameworks and key activities of intervention development and 
evaluation. The substantial evidence base for T2D prevention internationally and the 
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span of this evidence across the research spectrum promoted the potential of T2D 
prevention as a case study to inform my guideline analysis. This analysis, underpinned 
by my empirical T2D prevention research, informed my proposed new guidance 
framework. The resulting ‘evolutionary decision tree framework’ and its associated 
diagram includes staged summative evaluation of efficacy (trial of an optimal 
intervention under ideal conditions), effectiveness (trial of a pragmatic intervention in 
the real world) and implementation (monitoring and sustainability). Intervention 
design loops, prior to each summative evaluation stage, are proposed to promote 
intervention optimisation with stage relevant key activities. Following each summative 
evaluation necessary decision points regarding progress and feedback are included in 
the framework. 
The position of health economic evaluation in this proposed framework is unclear. 
Determination of cost and benefit of lifestyle preventive intervention is particularly 
challenging. The staged progression concept suggests that ‘does the intervention work’ 
should precede ‘will the intervention work efficiently in a real world setting.’ However, 
return on investment is important for commissioned interventions and early 
indications both of likely cost benefit returns and opportunities for cost savings in 
intervention delivery are important. 
8.2 Strengths and limitations of my empirical work and guideline analysis 
8.2.1 Type 2 diabetes prevention: my empirical work 
My empirical work to date is limited by the lack of a formal effectiveness evaluation of 
an implementable intervention. On one hand, although efficacy of the EDIPS 
intervention was demonstrated, this intervention is not feasible for implementation 
nor efficient for service provision.200 On the other hand the NLNY intervention, where 
implementation as service provision has been shown to be feasible on a small scale in 
one area of the UK, has not been formally evaluated for effectiveness and efficiency. 
My NLNY intervention development experience has highlighted the need for 
consideration of context and practicalities in intervention design, alongside an 
evidence based protocol of proven efficacy, providing a platform for feasible and 
acceptable ‘real world’ intervention delivery. The extensive NLNY pilot work, with 
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associated qualitative process evaluation, strengthens the potential for a pragmatic 
effectiveness evaluation of an implementable and sustainable intervention model.  
Although the NLNY intervention development highlighted a need for adaptation to 
better engage ethnic minorities, for equitable service provision, the feasibility pilot of 
the culturally adapted NLNY intervention is incomplete. It would be premature to plan 
effectiveness evaluation of the adapted NLNY intervention.  
8.2.2 Analysis of intervention guidance  
In my guideline analysis I reviewed several previous models although this was not a 
systematic review. An advantage of using T2D prevention as a case study for this 
analysis is the extensive evidence base and span that allows the evolutionary 
progression of T2D prevention to be traced. However, this intervention model with a 
precisely defined clinical outcome is tightly focussed. Public health interventions have 
a much broader range and do not necessarily ‘grow’ from evidenced aetiological and 
scientific roots. 
The use of three evidence sources (guidance review, T2D case study and my empirical 
research experience) to inform a common output contributes to the strength of the 
analysis. However the insight that my empirical experiences provide for the analysis 
should be tempered by the potential for a biased and subjective personal view. As this 
is my PhD thesis, the findings might be more subjective, even with the valued input 
from others, than would be the case had the same evidence been reviewed and 
analysed by an expert committee and discussed to derive a consensus. Procedures for 
guidance development used by NICE employ an expert committee consensus 
approach, however, this approach is not without limitations and may be particularly 
difficult in the complicated and diverse context of guideline development.101 
Despite the extensive evidence base for T2D prevention, there is very little evidence 
around sustainability of service provision, or methods by which sustainability might be 
promoted or evaluated. This limitation of the analysis affects the proposed new 
intervention guidance. Similarly, although I have recognised unanticipated intervention 
benefits I have not expanded on methods to assess and include these in intervention 
guidance.209, 210  
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My framework diagram was intended to look simple. However, in comparison to 
earlier model diagrams, including the MRC 2000 and MRC 2008 framework diagrams it 
appears more complex. By using a building block concept, with standard and familiar 
formats common to flow charts and decision trees I sought to clarify a complex 
process. It is not clear whether this diagram will succeed in making guidance easier to 
assimilate and apply. 
A framework diagram, even with detailed explanation and accompanied by a fairly 
comprehensive list of key activities, does not constitute complete guidance. This 
proposal is only a starting point for the development of new guidance and will require 
further analysis and testing. In particular it will be necessary to test the application of 
this framework to other case studies to assess its generalisability. 
8.3 Relation to other work 
8.4.1 Type 2 diabetes prevention  
As described previously the main T2D prevention efficacy trials recruited participants 
with IGT, 6, 9 whereas effectiveness studies to date have mostly used risk scores for 
recruitment.9 NICE guidance advocates a risk score followed by a blood test to identify 
high-risk individuals.9 However the appropriate combination of risk score values and 
blood test cut-points is not known.  The recent decision by WHO,63 following an earlier 
decision by ADA,211 to recognise an HbA1c value (repeat measure) as a diagnostic 
criterion for diabetes has expanded the design opportunities for a pragmatic T2D 
preventive intervention. In the RCT reported by Saito et al212 sub-group analysis 
suggested the utility of HbA1c to identify high-risk individuals for effective preventive 
intervention. However, as this trial recruited participants with IFG the utility of HbA1c 
as a single risk criterion remains unclear.  
Most of the translational T2D preventive interventions to date have relied principally 
on behaviour change counselling. In a European collaboration, resulting from the DE-
PLAN project, the ‘European Perspective on Diabetes Prevention: development and 
Implementation of A European Guideline and training standards for diabetes 
prevention’ (IMAGE) 213 a set of practical procedures have been collated and presented 
as an intervention toolkit.214 A comprehensive and systematic review of behaviour 
change interventions for weight management, increased physical activity and healthy 
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eating, that was prepared for the IMAGE group was also presented to the relevant 
NICE PDG.215  
The novelty of the NLNY intervention is in its experiential learning mode of delivery 
structured round physical activity sessions followed by reflection, with counselling and 
advice.216 As both the DPS and DPP intervention protocols included group delivered 
physical activity sessions they contribute to the evidence base for the design of 
NLNY.12, 114 The NLNY intervention may cost more to deliver than a counselling based 
intervention, but it is not yet clear which model would be more cost-effective.  
There have been other lifestyle change interventions to address diabetes risk, apart 
from EDIPS-Newcastle and NLNY, conducted in the UK.217 In the PREPARE RCT218 Yates 
et al recruited ninety-eight overweight or obese individuals with impaired glucose 
tolerance. Participants were randomized to receive an advice leaflet, 3-hour structured 
education programme aimed at promoting physical activity, or 3-hour structured 
education with use of a pedometer. Data for seventy-four percent of participants were 
analysed at 24 months of follow-up. A statistically significant reduction in 2hrPG of 
−1.6 mmol/l (−0.4 to −2.7) was seen in the pedometer group compared with the 
control group, but no significant difference in the education-only group. Larger studies, 
‘Let’s Prevent’ and ‘Walking away’ based on a similar educational model are under 
way.219, 220 
A different small intervention trial based on motivational interviewing sessions to 
promote lifestyle change reported in 2008. 221  Exercise was assessed by self-reported 
questionnaire and showed a non-significant increase in the intervention compared 
with the control group at six months of follow-up. In the Pro-Active trial of an 
intervention to promote physical activity targeted to sedentary adults with a parental 
history of T2D, 222there was no significant difference in physical activity at one year of 
follow-up between intervention and control groups.223  
Recruitment to a large trial, The Norfolk Diabetes Prevention Study 224  based on 
fasting plasma glucose  (IFG) (and now including a large HbA1c only sub-group 
following a protocol amendment) to define ‘pre-diabetes’ is currently underway. The 
intervention relies on group based counselling with mentor support to promote 
increased exercise and healthy diet. Participants are recruited via primary care and 
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pharmacies. For recruitment IFG may not be the most efficient option.212 In sub-group 
analysis Saito et al found no intervention effect in the isolated IFG sub-group. 
Primary prevention of T2D is an alternative approach to screening for early detection 
of T2D for the purpose of preventing the development of disease complications 
including CVD. In this respect the recent findings of the ADDITION trial that aimed to 
assess the effect of a T2D screening programme, with intensive multifactorial 
treatment for those diagnosed with T2D, on mortality are relevant.78 The response to 
screening invitations was high at 73%, but the authors did not find a significant 
reduction in CVD, cancer or diabetes-related mortality as a result of the intervention. 
This is an important study in that the findings may support the need to consider 
intervention at an earlier time in the T2D trajectory. Screen detected diagnosis of 
diabetes occurs when hyperglycaemia related beta-cell and vascular damage is already 
probable, which limits the potential for secondary prevention.78, 225 It is likely that 
remission of beta-cell damage would involve extreme lifestyle change that may not be 
sustainable58 and initiating less extreme intervention that might be easier to maintain 
at an earlier stage may be a better approach. However any beneficial effect of T2D 
preventive intervention on CVD outcomes is yet to be determined.226 
An intervention based on the GTT intervention protocol, targeted to people at 
increased risk of CVD has recently been developed.227 
8.3.2 Analysis of intervention guidance  
To what extent developments of newly proposed intervention guidance has built on 
the review and analysis of previously proposed intervention guidance is not always 
explicit. The paper by Campbell N et al30 is one exception. The authors analyse the 
MRC 2000 framework 19 using case study examples and specifically state their 
intention to focus on early stages of intervention design. Similarly Ogilvie et al present 
their translational framework41 as resulting from a case study of public health research 
in the UK and the Cooksey report.10 The PRISM model development was informed by 
examination of existing models, identified from a literature review, and authors’ 
experience. It is built on key elements of previous models.32, 228. The model of diffusion 
in service organisations by Greenhalgh et al 37 is described as being derived from a 
systematic review of empirical research studies in health service delivery. In this 
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analysis I have sought to examine the historical evolution of guideline development 
with a focus on models summarised in framework diagrams. 
Many of the intervention guidance models are supported by case study analyses. As an 
example the MRC 2008 framework uses 14 case studies.20 Case studies 1,2 and 3 relate 
to the key early developmental elements, case studies 4 to 9 inclusive are primarily 
about study designs for evaluation, case study 10 focusses on understanding 
processes, 11 is about economic evaluation, 12 is about implementation issues, 13 
about reporting and 14 about involving users. Thus, these case studies are used to 
illustrate specific key elements in isolation. By contrast, my analysis, using T2D as a 
case study, relates to all key elements described in the MRC framework across 
sequential intervention development and evaluation stages. This broader analysis has 
the strength of coherence, but the limitation of a tightly defined focus. 
8.4 Implications for policy, practice and future research 
8.4.1 Type 2 diabetes prevention: policy and practice 
The diabetes world-wide pandemic highlights the importance of healthy lifestyles and 
the need for pragmatic and effective diabetes prevention.2 A rise in longevity needs to 
be accompanied by an extension of healthy life years for the benefit of individuals, 
their health services, societies, and economies.  For health service commissioners to 
confidently invest in preventive interventions they need resources to commit to 
successful programmes and evidence to justify the expenditure. Where commissioners 
see local need and interventions that ‘seem to work’ they may be reluctant to invest in 
effectiveness evaluation.229 Similarly where allocation of monies to treatment of 
current disease conditions competes with allocation of spending for preventive 
initiatives difficult choices are inevitable, especially at a local level.  
In the UK the NHS is over-burdened with people who are already suffering ill health. It 
seems opportune therefore to engage community services in the provision of 
interventions for primary prevention of chronic disease conditions. The move of public 
health to local authority responsibility should theoretically facilitate this shift.230 
However, current severe cost-constraints on local authorities mean there is a danger 
that the supposedly ‘ring-fenced’ budget meant for public health will be side-tracked 
to fulfil budget shortfall in non-health areas.201 Local authorities are not the primary 
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beneficiaries of cost saving through investment in disease prevention. The NHS is the 
beneficiary of reduced treatment costs. National policy makers urgently need to take a 
long term cross-sector view to ensure investment in prevention of non-communicable 
diseases and well-targeted research investment to obtain robust evidence.  
8.4.2 Type 2 diabetes prevention: my empirical work and future research 
Through working with service partners we have developed an evidence based and 
pragmatic T2D preventive intervention that is currently commissioned in the local area 
where it was developed.16 Evaluation of this intervention for effectiveness and 
efficiency is needed. Designing a study to achieve this, without losing the essence of 
the intervention is challenging. For a well conducted trial precision of participant 
inclusion and exclusion criteria are needed to support a sample size calculation. The 
additional burden of research data collection alters the intervention delivery, thus 
introducing tension between adequate data and minimal respondent burden and 
there is  tension between the precision with which an intervention protocol is defined 
and allowance for staff autonomy.20 134 Also evaluation of lifestyle intervention is 
complicated by control group assessment and data collection that alerts them to 
beneficial lifestyle changes.90 This is different from drug RCTs, which are likely to be 
placebo controlled and blinded.  
We are currently progressing plans for an effectiveness evaluation of the NLNY 
intervention. Initially this will involve evaluation of the original version of the NLNY 
intervention that principally engaged the local white population. The most likely 
evaluation study design will be a cluster RCT to incorporate the community based 
recruitment that is an inherent part of the NLNY intervention model. We anticipate 
that effectiveness evaluation of the original NLNY intervention will be followed by 
further effectiveness evaluation of the NLNY adaptation for ethnic minority 
participants and those with previous gestational diabetes. 
In principle an adaptation of the NLNY intervention may also have potential for 
secondary prevention of diabetic complications. This is an important avenue for future 
research because any risk assessment procedure designed to identify high-risk 
individuals is also likely to uncover those with undiagnosed prevalent T2D and there 
are ethical concerns regarding restrictive provision of intervention opportunities to 
primary prevention. 
93 
 
Effective lifestyle intervention for T2D prevention is likely to promote additional 
collateral benefits for the health of participants and others within their sphere of 
influence, such as children and grandchildren. It may not be possible to fully include 
these benefits of lifestyle intervention in a cost-effectiveness evaluation. 
8.4.3 Guideline analysis: policy and practice 
Clearer guidance for developing and evaluating complex interventions to improve 
health could be productive in ensuring more realistic and well developed research 
proposals for evaluating intervention effectiveness and efficiency. In particular a 
staged building of evidence from efficacy evaluation, via small scale and tightly 
targeted effectiveness evaluation, with substantial feasibility piloting at each stage 
should lead to more efficiently allocated research resources.  If an intervention effect 
is already proven in ideal conditions (efficacy evaluation),26 then demonstration of 
intervention effectiveness is theoretically possible. The emphasis in effectiveness 
evaluation is then on developing a commissionable intervention, which is likely to 
involve partnership working that includes commissioners and delivery staff, as well as 
constructing a robust effectiveness evaluation study. Policy makers and funders have 
the power to drive research with evaluation of pragmatic and sustainable intervention 
programmes by targeting research resources. 
8.4.4 Guideline analysis: future research 
A framework diagram, even with accompanying explanation and a fairly 
comprehensive list of key activities, does not constitute complete guidance. This 
framework diagram is only a starting point for intervention guidance and will require 
further development and testing. In particular my proposed framework has been built 
on review and analysis of previous guidance supported solely by T2D prevention case-
studies. It will be necessary to test this framework with other case-studies to assess its 
generalisability.  
My proposed framework diagram was designed to be simple to interpret, but it is not 
clear whether this framework would succeed in making intervention guidance easier to 
apply.  
The principle that new guidance development should be built on the review and 
analysis of existing guidance is an important pointer for further research in this area.  
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